CURRICULUM VITAE FOR

DR. CAROLYN L. WESTHOFF

**SECTION AND DESCRIPTION PAGES**

1. Date of CV Preparation 2
2. Personal Data 2
3. Academic Appointments, Hospital Appointments, 2-3

& Other Work Experience

1. Education 3
2. Training 3
3. Explanation of any gaps in work/training/education 3
4. Licensure and Board Certification 4
5. Honors & Awards 4
6. Academic Service 5-6
7. Professional Organizations and Societies 6-9
8. Fellowship and Grant Support 9-17
9. Educational Contributions 18-20
10. Publications
	1. Peer-Reviewed Research Publications 21-44
	2. Reviews, Chapters, Monographs, Editorials 45-54
	3. Case Reports 54
	4. Letters to the Editor 54-55
	5. Other Non-Peer Reviewed Publications 55-66
11. Invited and/or Peer-Selected Presentations at 67-70

Regional, National or International Levels

1) **Date of Preparation of CV** 11.12.2019

2) **Personal Data**

Name: Carolyn L. Westhoff

Contact Information: 622 W. 168th Street

 PH 16-69

 New York, NY 10032

 clw3@cumc.columbia.edu

 212-305-4805(W)

Birthplace: Michigan

Citizenship: U.S
NPI: 1386676575

3) **Academic Appointments, Hospital Appointments, and Other Work Experience**

***Academic Appointments***

1986 – Present **Department of Obstetrics & Gynecology,**

**Columbia University** (New York, NY)

2015 – Present Sarah Billinghurst Solomon Professor of Reproductive Health

2014 – 2015 Wyeth-Ayerst Professor of Women’s Health

2000 – Present Director, Division of Family Planning and Preventive Services

2000 – 2014 Professor of Obstet Gynecol

1993 – 2000 Associate Professor of Clinical Obstet Gynecol

1986 – 1993 Assistant Professor of Obstet Gynecol

1986 – Present **Department of Epidemiology,**

**Columbia University** (New York, NY)

2000 – PresentProfessor of Epidemiology

1993 – 2000 Associate Professor of Public Health (Epidemiology)

1986 – 1993 Assistant Professor of Public Health (Epidemiology)

2000 – Present **Department of Population & Family Health,**

**Columbia University** (New York, NY)

Professor of Population & Family Health

1984 – 1986 **Department of Obstetrics & Gynecology, State University of New York (S.U.N.Y.), Health Sciences Center at Brooklyn (formerly, Downstate Medical Center)** (Brooklyn, NY)
Assistant Professor

***Hospital Appointments***

1986 – Present **Columbia University Medical Center, New York Presbyterian Hospital** (New York, NY)

2000 – Present Attending Physician

1993 – 1999 Associate Attending Physician

1986 – 1993 Assistant Attending Physician

2009 – 2012 Clinical Director, Ambulatory Ob/Gyn

2001 – 2012 Medical Director, Special GYN Services

1988 – 2012 Medical Director, Family Planning Clinics

1984-1986 **State University Hospital and Kings County Hospital Center** (Brooklyn, New York) Attending Physician

***Other***

2012 – 2018 **Planned Parenthood Federation of America**

(New York, NY) Senior Medical Advisor

4) **Education**

1982 – 1983  **London School of Hygiene and Tropical Medicine**

M.Sc. with distinction, Epidemiology, 1983

1973 – 1977  **University of Michigan** M.D., 1977

1969 –1972 **University of Michigan** B.S. with distinction, Zoology, 1972

5) **Training**

2001 – 2002 **Executive Leadership in Academic Medicine (ELAM)**, Fellow

1983 – 1984 **Department of Community Medicine and General Practice, University of Oxford** (Oxford, U.K.), Research Fellow

1981 – 1982 **Department of Obstetrics & Gynecology, S.U.N.Y. - Downstate Medical Center** (Brooklyn, NY), Chief Resident

1978 – 1981 **Department of Obstetrics & Gynecology, S.U.N.Y. - Downstate Medical Center** (Brooklyn, NY), Resident

1977 – 1978 **Department of Internal Medicine, Henry Ford Hospital** (Detroit, Michigan), Intern

6) **Explanation of Gaps**

None

7) **Licensure and Board Certification**

1978 – Present New York State Medical License, renewed annually

1986 – Present American Board of Obstetrics and Gynecology

* Certified, 1986; Recertified, 2006, 2014
* Annual board certification, 2005-2017

1978 – Present National Board of Medical Examiners

8) **Honors & Awards**

2018 Planned Parenthood Federation of America/National Medical Committee, Michael S. Burnhill Lectureship Honoree

2016 Alliance for Continuing Education in Health Professions, Award for Outstanding Outcomes Assessment, 2016 (see Harper et al, 2015)

2015 NYC Department of Health and Mental Hygiene, Most Impactful Article of 2013, Granted 2015 (see Langston et al, 2013)

2013 **Association of Reproductive Health Professionals, Alan F. Guttmacher Lectureship Honoree**

2011 Obstetrics and Gynecology, Roy Pitkin Award for best article

2010 Society of Family Planning, Lifetime Achievement Award

2010 Physicians for Reproductive Choice and Health, Dr. Wm. Rashbaum Award

2010 American Women’s Medical Association, Women in Science Award

2009 National Family Planning and Reproductive Health Association, Dr. Allan Rosenfield Award for Access to Quality Family Planning

2008 Obstetrics and Gynecology, Roy Pitkin Award for best article

2007 Institute of Medicine, National Academy of Sciences, elected to membership

2007 North American Menopause Society, Innovations in Perimenopausal Contraception Research Award

2006 American Gynecological and Obstetrical Society, elected to membership

2005 National Abortion Federation, C. Lalor Burdick Award

2004 New York Civil Liberties Union, Reproductive Rights Project Award

2003 National Coalition for Women’s Health, Shirley Sacks Award

2002 University of Michigan, Abram Sager Lectureship,

2002 Planned Parenthood of NYC, Women Making History Award

2001 American Congress of Obstetricians and Gynecologists, Women’s Health Leadership Program

1992 New York Obstetrical Society, elected to membership

1991 CUMC Comprehensive Cancer Center, Elaine B. Lesser Prize

1991 Columbia University School of Public Health, Calderone Prize

1982 – 1987 Milbank Memorial Fund Scholar

9) **Academic Service**

***Department of Obstetrics and Gynecology, Columbia University***

2013 – 2015 Departmental Committee on Appointments & Promotions

2008 – 2013 Departmental Committee on Appointments & Promotions (Chair)

2007 – 2012 Education Committee

2002 – Present Departmental Executive Management Committee

1991 – 1996 Departmental I.R.B.

1989 – 1995 Vanderbilt Clinic-4 Board of Managers

1989 – 2012 Family Planning Quality Assurance Committee (Chair)

1986 – 1989 Medical Records Committee

***Mailman School of Public Health, Columbia University***

2011 Sociomedical Sciences, ad hoc search committee for dept. chair

2009 Environmental Sciences, ad hoc search committee for dept. chair

2006 – 2009 Committee on Appointments and Promotions

1997 – 1999 Gonorrhea Community Action Project (GCAP), Advisory committee

1997 – Present Center for Population and Family health, Research Review comm.

1995 Health Policy, ad hoc search committee for department chair

1994 – 1995 SPH Steering Committee

1989 – 2012 Center for Population and Family Health, Family Planning Clinics,

Senior staff committee

1990 – 2012 Standing Committee on Research

1990 – 1998 Epidemiology, Ph.D. Subcommittee

***Columbia University Medical Center***

2018 Alpha Omega Alpha Task Force (Chair)

2018 School of Nursing, Search Committee for Dean

2017 – 2022 Socio-Medical Sciences Training Grant in Gender, Sexuality, and Health. External Advisory Board. (Mailman SPH)

2014-present Senior Learning Environment Advisor

2013 – 2019 Irving Center for Clinical Research (CUMC-CTSA), Scientific Advisory Board Member

2009 – 2010 School of Nursing, Search Committee for Dean

2002 – 2012 Committee to Review Complaints

2003 – 2013 Institutional Review Board, alternate

1996 – 2000 Institutional Review Board (including administrative committee)

1994 – 1995 Cancer Protocol Review Committee

1994 – 2007 P & S Faculty Council

1993 – 1996 Comprehensive Cancer Center, Women's Cancers Program (Chair)

1993 – 1996 CPC, Advisory Committee

1992 CPC, Ad hoc committee to reinstitute the CPMC tumor registry

1991 – 1994 Curriculum Revision Committee, College of P&S,

working group on sexuality and reproductive health (chair)

10) **Professional Organizations and Societies**

2007—Present Institute of Medicine (Now National Academy of Medicine),

 Section 5 Chair, 2015-2017

Section 5 Vice-Chair, 2013-2015

2007 – 2012 Planned Parenthood Federation of America,

Board of Directors, 2008-2012

2005 – Present Society of Family Planning,

 Past-President, 2015-2017

President, 2013-2015

President elect, 2011-2013

Scientific Committee chair, 2011-2013

Founder and Board Secretary 2005-07

2005 – 2011 Guttmacher Institute, Board of Directors

2004 – 2005 American Medical Women’s Association Foundation, Board of Directors

1992 – Present New York Obstetrical Society,

Executive Committee, 1999-2008

President, 2005-2006

1986 – Present Association of Reproductive Health Professionals,

Board of Directors, 2003-2009

1986 – Present American College of Obstet. Gynecol., Fellow

 Annual Clinical Meeting

Course Chair, Postgraduate Course (060) on Contraception and Abortion, 2000-2005

ACOG District II

Legislative Committee, 2006-2009

Chlamydia Testing Workgroup, 2002

Emergency Contraceptive Advisory Board, 2002

Primary care committee, 1994-1995

***Consultative: Federal and Other Government***

2014 – 2015 CDC, Medical Eligibility Criteria 2nd Edition Working Group

2012 – Present FDA BRUDAC, Division of Advisory Committee and Consultant Management, Member

2009 – 2011 CDC, Selected Practice Guidelines for Contraceptive Use, Expert Working Group

2009 – 2011 NYC, DOHMH, Bureau of Maternal, Infant, and Reproductive Health. Healthy Teens Initiative, Consultant

2008 – 2012 NYC-DOHMH, Reproductive Health Training to School Based Clinics throughout New York City, Consultant

2008 NIAID, Identifying Research Gaps, Consultant

2008 – Present CDC, Medical Eligibility for Contraceptive Use, Expert Working Group

2006 – 2009 NYC-DOHMH, Emergency Contraception Awareness & Access Program (ECAAP), Consultant

2004 – Present NICHD, Contraceptive Clinical Trials Network, Steering Committee

2003 NICHD, DMPA and Diabetes Work Group

1998 – 2003 Agency for Health Care Policy and Management (now ARHQ), U.S. Preventive Services Task Force, Member

1998 – 2004 Agency for Health Care Policy and Management, Ms trial. Data Safety and Monitoring Board, Chair

1998 – 2005 NICHD, Efficacy trial of spermicidal agents (FHI). Data Safety and monitoring Board, Chair

1996 –1997 NIH, Consensus Development Conference on Breast Cancer Screening in Women aged 40-49, Panel Member

1995 NICHD, Research on Long-acting Contraception, Panel Member

1995 – 2011 NCI, PLCO Trial, Monitoring and Advisory Panel

1994 NIH, Consensus Conference on Ovarian Cancer, Speaker

1994 – 1997 NIH, DRG. Epidemiology and Disease Control-2 study section, Member

1993 – 1994 Tobacco-Related Disease Research Program (California). Member, Epidemiology Study Section

1991 NCI, Ovarian Cancer Epidemiology Advisory Group

1991 – 1993 NIH, DRG, Epidemiology and Disease Control-2 study Section, Special Reviewer

1990 – Present NICHD, Member, ad hoc Review Groups, and Site Visitor

1989 – 1991 NICHD, Member, Advisory Working Group on Breast Cancer and Oral Contraceptives

1989 NICHD, Member, Contraception and Sexually Transmitted Disease Advisory Group

1988 – 1989 Office of Technology Assessment (Preventive Services under Medicare Project), Cervical cancer screening in elderly women; Scientific Advisory Group

1987 NHLBI, Member, ad hoc Review Group, Postmenopausal estrogen and progestin intervention (PEPI) trial

***Consultative: Non-government***

2016-2019 NQF Perinatal and Reproductive Health Workgroup, Member

2015 NCQA, Women’s Heath: Approaches to Improving Unintended Pregnancy in the United States, Consultant

2014 Bayer: A Multi-Center, Multi-National Clinical Study to Evaluate the Safety and Effectiveness of the Essure® (Model ESS505) Device to Prevent Pregnancy in Women Who Are Seeking Permanent Contraception, DSMB Chair

2013 – Present WHO, Geneva – Medical Eligibility Criteria and Selected Practice Recommendations Revisions, Scientific Advisor

2012 – 2014 NCQA Cervical Cancer Screening Monitoring and Advisory Panel

2012 – Present ZEG, Choice of Estrogens and Long-term Investigation of Nomegestrol Acetate - International Active Surveillance Study (INAS-CELINA). Berlin, Germany. DSMB Member.

2011 – Present Nexplanon Observational Risk Assessment Study (NORA). Berlin, Germany. DSMB Member.

2009 – Present ZEG, European Active Surveillance (EURAS-IUD). Berlin, Germany. DSMB Member.

2008 – Present ZEG, Transatlantic Active Surveillance of Cardiovascular Safety of NuvaRing (TASC). Berlin, Germany. DSMB Member.

2008 – Present ZEG, International Active Surveillance Study (INAS) of Oral Contraceptives containing Drosperinone. Berlin, Germany. DSMB Member.

2008 – 2012 Accreditation Committee on Graduate Medical Education (ACGME). Obstet Gynecol Residency Review Committee.

2007 – 2012 ZEG, International Active Surveillance (INAS) Cohort Study. Berlin, Germany. DSMB Member.

2005 Royal College of Obstetricians and Gynaecologists. Fertility Control, 49th RCOG Study Group

2003 Association of Professors of Gynecology and Obstetrics, Women’s Health Interdisciplinary Curriculum Development Panel

2003 – 2010 Planned Parenthood Federation of America, National Medical Committee. Executive Committee, 2003-10; Vice-Chair, 2006-2007; Chair, 2008-2010.

2001 – 2004 Medical Abortion Education Project (MAEP), Curriculum Development and Faculty Training. Jointly sponsored by NAF, PRCH, ARHP and AMWA

2002 – 2005 Good Housekeeping Award for Women in Government, Selection Committee Member

2001 Royal College of Obstetricians and Gynecologists, Sexual and reproductive health in the medical curriculum, Expert Consultant

1998 – 2000 Open Society Institute, Reproductive Rights Program. Fellowship project evaluation

1997 – 2003 ACLU Reproductive Rights Project, affidavits and testimony for plaintiff in Michigan, New Jersey, and others.

1997 – 2000 Japanese Professional Women’s Coalition for Sexuality and Health. International Advisor

1997 – 2005 NARAL Foundation, Advisory Committee

1993 – 1995 Physicians for Reproductive Choice. Founder and Steering committee member

1993 – 2004 American Medical Women's Association. Reproductive Health Initiative Advisory Committee, Communications Subgroup Chair, 1993 -1995. Co-chair, 1995-1999, Chair 1999-2004.

1991 – 2006 Planned Parenthood of New York City. Member, Medical Committee 1991-94, Chair 1994 - 2006. Board of Directors, 1994- 2006.

***Editorial***

2013 – Present CONTRACEPTION, Editor in Chief

2011 – 2012 British Journal of Family Planning and Reproductive Health Care, Editorial Board

2004 – 2007 The Forum (for women’s health care), Editorial Board

1998 –1999 Expert Connections Forum (e-mail/web-based physician education program), Editorial Board

1998 Managed Care Interface in Practice: Women’s Health Issues, Editorial Board

1997 – 1999 AMA, Women’s Health Web Site, Editorial Board

1993 – 2012 CONTRACEPTION, Editorial Board

1992 – 2010 Dialogues in Contraception, Co-editor

11) **Fellowship and grant support**

***Present Support***

5/2010-11/2023 Medicines 360: A phase 3, multi-center, open-label study of a levonorgestrel-releasing intrauterine system system for long-term reversible contraception. ($689,792). P.I. Westhoff

7/2018-6/2021 A phase 3 prospective, multi-center, single-arm, open-label study to evaluate VeraCept™, a long-acting reversible intrauterine contraceptive for contraceptive efficacy, safety, and tolerability. (Contract) Site P.I. Westhoff

12/2016-12/2021 Sebella Pharmaceuticals contract. Evaluation of the effectiveness, safety, and tolerability of LevoCept (Levonorgestrel-Releasing Intrauterine System) for long-acting reversible contraception. P.I. Westhoff

12/2016-12/2021 Estretra SPRL contract. A multicenter, open-label, single-arm study to evaluate the contraceptive efficacy and safety of a combined oral contraceptive containing 15 mg Estetrol and 3 mg Drospirenone. P.I. Westhoff

3/2019/6/2020 Society for Family Planning Research Fund Grant. Auriculotherapy as adjunct for pain management during medication abortion: a randomized, double-blinded, three-arm trial. ($330,425) P.I. Westhoff

2/2019-6/2020 Society for Family Planning Research Fund Grant. Auriculotherapy as adjunct for pain management during first trimester surgical abortion: a randomized, double-blinded, three-arm trial. ($15,000) Mentor to P.I. Johana Oviedo

9/2014 - 9/2020 NICHD- HHSSN27501300010I T03: Main Study for a Multicenter, Open Label Randomized Study of the Efficacy, Cycle Control and Safety of a Contraceptive Vaginal Ring Delivering a Daily Dose of Nestorone® and Estradiol. ($423,339) P.I. Westhoff

7/2016 - 06/2020 NICHD—HHSN27520130001 T01: A multi-center, randomized study of the efficacy of ulipristal acetate (UPA) 30 mg, levonorgestrel (LNG) 1.5mg, and LNG 3.0 mg for emergency contraception (EC) in women with weight *≥* 80kg. ($1,382,915) Site P.I. Westhoff

6/2013 - 6/2020 NICHD- HHSN275201300010I/HHSN27500001: Contraceptive Clinical Trials Network- Female Sites: Core Functions Activities Task Order. ($234,896) P.I. Westhoff

9/2015– 9/2022NICHD- SN27520130010I TO4: Randomized trial to determine effectiveness, insertion characteristics and side effects of copper IUD insertion devices. ($358,353) Co-I Westhoff, P.I. Paula Castano

***Past Support***

2/2018-6/2019 Society for Family Planning Research Fund Grant. The effect of dolutegravir-based ART on serum etonogestrel levels in HIV-infected women using contraceptive implants in Botswana ($100,000) Mentor to P.I. Ian Bishop

7/2018-6/2019 Society for Family Planning Research Fund Grant. Comparison of claims based vs. electronic health record contraceptive performance measures for quality improvement ($100,000) Mentor to P.I. Surya Cooper

7/2016 - 06/2018 RSNA Research Scholar Grant - RSCH1607: The Effect of Ulipristal Acetate (UPA) on Breast Cell Proliferation Measured by Ki-67 and Breast MRI BPE and its Potential as a Chemoprevention Agent ($150,000) Mentor to P.I. Richard Ha

7/2017-6/2018 Society for Family Planning Research Fund Grant. Auricular acupuncture as adjunct for pain management during first trimester abortion: a randomized, double-blinded, three arm trial. ($99,000). Westhoff, P.I., mentor to Chioma Ndubisi, MD.

7/2016- 7/2017 SFP Research Fund Grant -SFPRF10-T4: The effect of dolutegravir-based ART on serum etonogestrel levels in HIV-infected women using contraceptive implants in Botswana ($7,500) P.I. Westhoff, Mentor to Serena Liu & Nicholas Teodoro

7/2016 - 6/2017 Society of Family Planning. Can providers determine eligibility for medical abortion with transabdominal rather than transvaginal ultrasound? ($200,000) P.I. Westhoff, Mentor to Annie Fu and Caitlin Weber

5/2015 - 4/2016 Society of Family Planning - SFPRF15-22: Pharmacokinetic Study of Emergency Contraception in Normal and Obese Women. ($99,950) P.I. Westhoff, Mentor to Piyapa Praditpan

1/2014 - 1/2016 Laboratorios Leon Farma – CF111/303: A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, And Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) during 13 cycles. ($112,154) P.I. Westhoff

7/2013 - 12/2017 NICHD- HHSN275201300010I/HHSN27500002: A Multi-Center, Randomized Study to Evaluate the Pharmacokinetic and Pharmacodynamic profile, Contraceptive Efficacy and Safety of Daily Oral Low Dose Ulipristal Acetate. ($644,838) P.I. Westhoff

12/2011 - 6/2013 Columbia University Medical Center CaMPR: Identifying the physiological and pharmacological basis of venous thrombo-embolism in women who use estrogen-containing medications-focus on combination hormonal contraceptives. 12/11-03/12. (Phase I - 25,000) (Phase II - 75,000) P.I. Westhoff

5/2011 - 11/2013 Amphora Gel Study AMP001. A Multicenter, OpenLabel, Randomized Study of the Contraceptive Efficacy and Safety of Amphora Gel Compared to Conceptrol Vaginal Gel. ($46,622) P.I. Westhoff

3/2011 - 3/2013 NICHD HSN2752011000424/HHSN275200403374I: Central lab for the nestorone/estradiol-releasing vaginal ring for female contraception. ($511,301) P.I. Westhoff

3/2011 - 3/2013 NICHD HSN2752011000424/HHSN275200403374I: Core function activities task order. ($560,941) P.I. Westhoff

3/2011 - 3/2013 NICHD HHSN2752013000101: Nestorone/Estradiol-releasing vaginal ring study. ($557,285) P.I. Westhoff

3/2011 - 1/2012 NICHD HHSN2452011000684: Clinical evaluation of levonorgestrel butanoate for female contraception. ($13,984) P.I. Westhoff

11/2010 - 9/2012 Society of Family Planning: Pre/Post LARC. Pregnancy and Contraceptive Outcomes before and after LARC ($70,000) P.I. Langston, Co-P.I. Westhoff

5/2010 - 5/2015 Med 360- L102. A Phase 3, Randomized, Multi-Centered, Open Label Study of a Levonorgestrel Releasing Intrauterine System and Mirena for Long Term, Reversible Contraception up to Five Years. ($689,790) P.I. Westhoff

3/2010 - 1/2013 HRSA TextFluenz-Using technology to promote flu vaccination in underserved maternal and child populations. ($270,000) P.I. Stockwell, Co I. Westhoff

3/2010 - 6/2011 Pfizer WS417107: Self DMPA. (Investigator Initiated) Self versus Clinic Admistered Depot Medroxyprogesterone Acetate ($136,782.28) P.I. Westhoff

2/2010 - 1/2011 NICHD HHSN275201000019U: LNG Patch. Effects on the mechanisms of contraceptive efficacy and safety of two progestin-only patches containing different doses of levonorgestrel ($316,770) P.I. Westhoff

1/2010 - 6/2010 Merck: NuvaRing3 P04816. (Investigator Initiated) Three Month Extended Use of NuvaRing: Pilot Study. ($104,183) P.I. Westhoff

9/2009 - 2/2012 NICHD HHSN275200900099U: PATH Condom. Contraceptive Efficacy Evaluation of the PATH Female Condom ($264,738) P.I. Westhoff

9/2008 - 6/2009 Pantarhei Self-Sample Study. The feasibility and acceptability of sampling device for cervical cytology testing among low income women in New York City ($59,173) P.I. Westhoff

7/2008 - 6/2013 K01 HD055263-01A1. Fertility and Disadvantage among Low-Income Adults: A Mixed-Methods Approach. Mentor to P.I. Romero.

7/2008 - 6/2011 NYC-DOHMH. Provide reproductive health training to school based clinics throughout New York City. ($2,204,522) Co-I Westhoff

1/2007-12/2008 Bayer/Yaz Study to assess folate levels in RBC during oral administration of OC containing folate. ($245,000) P.I. Castano, Co-I Westhoff

1/2007 - 12/2008 Affinity Health Plan. "Txt now 2 decrease pregnancies L8tr" (a randomized trial of text messaging for OC continuation). ($192,883) Co-I. Westhoff, P.I.Castano,

12/2006 - 12/2008 NICHD HD43374002 Contraceptive Clinical Trials network: Clinical Trial of a novel hormonal contraceptive ring. P.I. Westhoff

5/2006 - 4/2008 Organon/Rumba Oral Contraceptive Study. Study to determine safety and contraceptive efficacy and menstrual cycle control of an oral contraceptive. ($87,857) P.I. Westhoff

4/2006 - 4/2009 New York City Department of Health. Emergency Contraception Awareness & Access Program (ECAAP). Co-I Westhoff

4/2006 - 3/2008 Duramed (Investigator Initiated) – Oral Contraceptive Pharmacokinetics in thin versus obese women. P.I. Westhoff

9/2005 - 9/2008 DHHS/OPA PAR-05-185 Impact of pack supply on contraceptive continuation. ($123,409) Co-I Westhoff, P.I. O'Connell

7/2005 - 6/2010 NICHD-R01-HD047816 Oral Contraceptive use along the US-Mexico border. Consultant Westhoff, P.I. Potter

7/2005 - 6/2008 NICHD-R01-HD045786 Obesity, ovarian suppression and oral contraceptives. ($257,765) P.I. Westhoff

4/2005 - 3/2011 NICHD HD43374002– Contraceptive Clinical Trials Network – Female Clinical Trial topic area- Core. ($820,446 Total) P.I. Westhoff

12/2004 - 11/2006 NICHD-R03-HD048547 Oral contraceptives and cytochrome p450 inducers. ($170,500) Co-I Westhoff, P.I. Davis

4/2004 - 2/2011 NICHD HD43374002 – Contraceptive Clinical Trials Network – Female Contraceptive Clinical Trial: A randomized controlled study of the efficacy, safety, and acceptability of C31G. ($360,000 Total) P.I. Westhoff

7/2003 - 8/2008 NICHD R01 AG15922-01. Alzheimer’s Disease Prevention Trial with Estrogens. ($1,276,640) Co-I Westhoff, P.I. Sano

5/2003 - 4/2005 Wyeth Pharmaceuticals – A Phase 3, multicenter, open-label study to evaluate the safety and efficacy of Levonorgestrel 90 ug and Ethinyl Estradiol 20 ug in a continuous daily regimen for oral contraception. ($125,270 Total) Co-I Westhoff, P.I. Davis

 1/2003 - 12/2003 Organon Pharmaceuticals. (Investigator Initiated) A randomized trial comparing the immediate initiation of the monthly vaginal ring for birth control and the immediate initiation of a triphasic oral contraceptive. ($138,238 Total) P.I. Westhoff

12/2002 - 10/2003 Besins International. A Phase II multicenter randomized controlled trial of 4-hydroxy tamoxifen gel for cyclical mastalgia. ($44,934 Total). P.I. Westhoff

10/2002 - 9/2004 ASPH/CDC/ATSDR. Quick Start: Improving Adolescents Contraceptive Compliance. ($500,000 Total) Co-I Westhoff, P.I. Rickert

 8/2002 - 8/2005 NICHD-R01-HD42413 - RCT of a Novel Oral Contraceptive Initiation Method. ($960,644 Total) P.I. Westhoff

 6/2002 - 5/2003 Ortho McNeil Pharmaceutical. A Randomized, open-label, multicenter study comparing the bleeding profile Ortho Evra -(Norelgestremin/Ethinyl Estradiol) continuous regimen versus Ortho Evra cyclic regimen. ($87,062.50 Total) P.I. Westhoff

6/2002 - 12/2002 Pharmacia. (Investigator Initiated) Observational study of novel methods for the initiation of the Depo-Provera contraceptive injection. ($36,374 Total) P.I. Westhoff

5/2002 - 8/2003 University of Pittsburgh (Subcontract) Mifepristone and Misoprostol for abortion 63 days gestation: RCT comparison of Misoprostol 6 to 8 hours versus 24 hours following Mifepristone. ($105,202.92 Total) P.I. Westhoff

1/2002 - 1/2003 Pharmacia & Upjohn. Contraception study of medroxyprogesterone acetate and estradiol cypionate injectable suspension administered subcutaneoulsy. ($150,125 Total) P.I. Westhoff

10/2002 - 9/2004 ASPH/CDC/ATSDR. Quick Start: Improving Adolescents Contraceptive Compliance Co-I Westhoff, P.I. Rickert

9/2001 - 8/2003 NICHD-R21-AT00836 - Effects of Hypericum Perforatum on Oral Contraceptives. ($250,000 Total) Co-I Westhoff P.I. Murphy

.

4/2001 - 7/2004 NICHD. N01-HD-13314 - A Randomized Controlled Study of the Efficacy, Safety, and Acceptability of BufferGel. ($293,784 Total) P.I. Westhoff

4/2001 - 4/2004 NICHD N01-HD13321 – RCT on Management of Early Pregnancy Failure: Clinical Centers. ($479,006 Total) P.I. Westhoff

12/2000 - 11/2002 NICHD-R03-HD39776 - Oral Contraceptives for Dysmenorrhea in Adolescent Girls. ($170,500 Total) Co-I Westhoff, P.I. Davis

10/2000 - 8/2002 Berlex. A Multicenter, Open-Label, Uncontrolled Trial with Levenorgestrel-Releasing Intrauterine System (LNG IUS) to Evaluate the Insertion and Counseling Procedures. ($82,250 Total) P.I. Westhoff

7/2000 - 6/2010 William and Flora Hewlett Foundation (2003-8871). Contraceptive Research and Training. ($1,080,000 Total) P.I. Westhoff

7/2000 - 6/2001 NICHD –R03-HD39239 - A Novel Oral Contraceptive Initiation Method. ($85,250 Total) Co-I Westhoff, P.I. Murphy

4/1999 Gynétics. A prospective, open label study of levonorgestrel 0.75mg tablets as an emergency contraceptive agent. ($25,925 Total) P.I. Westhoff

9/1998 - 8/1999 New York Community Trust. Adolescent girls with chronic illnesses: sexuality and contraception counseling project. ($40,000 Total) Co-I Westhoff, P.I. Soren

7/1998 - 6/2003 NIH (NIA) R01 AG15922-01. Alzheimer’s Disease prevention trial with estrogen. ($11,760,156 Total) Co-I Westhoff, P.I. Sano

7/1997 - 9/1998 Fan Fox and Leslie Samuels Foundation, Inc. Adolescent girls with chronic illnesses: sexuality and contraception counseling project. ($68,500 Total) Co-I Westhoff, P.I. Soren

5/1997 - 12/1998 Pharmacia & Upjohn. Multi-center open-label clinical trial of the contraceptive effectiveness and safety of Cyclo-Provera ($85,000 Total) P.I. Westhoff

4/1996 - 3/2000 NICHD. Data Coordinating Center for the Reproductive Medicine

Network ($3,000,000 Total) Co-I Westhoff, P.I. Canfield

7/1995 - 6/2002 Wyeth-Ayerst Laboratories. Norplant System observational cohort study. ($591,626 Total) P.I. Westhoff

1/1995 - 12/1999 SRA Technologies, Inc (under contract to NCI). Ovarian and breast cancer in an infertile cohort (co-author of NCI protocol). ($239,964 Total). P.I. Westhoff

12/1994 - 6/1995 The Population Council. Evaluation of the efficacy, safety and acceptability of mifepristone and misoprostol in inducing abortion in

pregnant women with amenorrhea of up to 63 days. ($206,700 Total) P.I. Westhoff

7/1994 - 6/1996 NCI - RO3 CA64194-01. Family history of cancer in women with ovarian tumors. ($49,978) P.I. Westhoff

10/1993 - 9/1994 NCI - RO3 CA63016-01. Germinal inclusion cysts of the ovary: the epidemiology. ($49,995) P.I. Westhoff

9/1992 - 8/1997 NICHD Decision-making concerning Norplant use. ($247,391) Medical advisor Westhoff, P.I. Davidson

5/1992 - 4/1994 NCI - RO3-CA57404-01. Infertility and Ovarian Cancer: A Pilot Study. ($49,993) P.I. Westhoff

1991 - 1992 American Cancer Society - #IRG-177A. Occurrence and epidemiology of germinal inclusion cysts of the ovary. Continuation of work funded by Lesser Prize and Calderone Award. ($8,000) P.I. (effort as needed) Westhoff

7/1990 - 6/1995 NCI - CA095299. Training Program in Cancer Epidemiology, Biostatistics and Environmental Sciences. ($286,416) Co-I (effort as needed) Westhoff

1991 - 1994 NCI-RO1-CA50658. Case Control Study of Benign Ovarian Neoplasms. ($308,627) P.I. Westhoff

8/1988 Columbia University Comprehensive Cancer Center, Institutional Research Grant. Use of transvaginal sonography for screening menopausal ovaries. ($15,000) P.I. Westhoff

6/1988 NCI-RO3-CA47827. CA-125 levels in the blood of normal women. Small grants program for epidemiology. ($20,000) P.I. Westhoff

1985 - 1991 NICHD Contract # N01-HD-52908. Luteal Phase Progesterone Level Changes Following Tubal Sterilization. Co-I Westhoff, P.I. Gentili (?)

1982 - 1987 Milbank Memorial Fund Scholar. ($300,000).

***Pending Support - none***

12) **Educational Contributions**

***Department of Obstetrics and Gynecology***

* Division of Prevention and Ambulatory Care, Division research meeting 1 hour weekly since 2001.
* Contraceptive options for the 1990's. June, 1991. Eight-hour CME course (course director). Multiple single lectures in annual department CME courses.
* Lectures to third year medical students, 16 hours per year since 1989.
* Journal Club for residents, monthly 1987 -1996.
* Biostatistics, 1987,1989,1991,1993. Enrollment: 6 clinical post-doral fellows per semester
* Director, Family Planning Fellowship, 1997-2013; co-director 2013-present. 19 fellows graduated. Four fellows have been promoted to associate professor; 3 of the 4 first fellows are now fellowship directors themselves.

***College of Physicians & Surgeons***

* Pediatrics, Adolescent Medicine Fellowship, Mentor and Scholarship Review Committee, 2008-Present.
* Pharmacology, second year students, Contraception, 1998-2009.
* Fourth year medical students, clinical selective, monthly, 1997- 2009**.**
* Clinical Practice I selective supervisor, for 1st Year medical students, 1996-2004
* Reproductive Health (course director), fourth year elective, 1995 onward. (vanguard site for the AMWA Reproductive Health Initiative).
* Sexuality and Reproduction (for Clinical Practice course), first – third year medical students. 1993 - 2008.
* Epidemiology section leader, first year medical students, 1987-1990, 1992.

***Departments of Epidemiology and Population & Family Health, School of Public Health***

* Public Health Aspects of Reproductive Health PH 8605, guest lecturer, 2007- to present
* Population & Family Health 8675, guest lecturer 2007 -annually
* Epidemiology 8691, guest lecturer 2007- annually
* Epidemiology 9400, guest lecturer,1999

-doctoral tutorial, endometrial or breast cancer

* Epidemiology 8422, guest lecturer
* Epidemiology 6400, guest lecturer, 3 semesters per year – 1990-1999.

-screening methodology

* Epidemiology 9480, course director, fall, 1990
* Comprehensive examinations, 1991, 1993, 1995, 1996 , 2008

-general exams

-specialty exams (cancer).

* Thesis sponsorships (Epidemiology)

 H. Jones, Ph.D., 8/10

 K. Hall, Ph.D, 6/10 (in Nursing)

 C. Morroni, Ph.D., 5/07

 S. Kizelnik, Ph.D., 7/02

J. Britton, Ph.D., 7/98

E. Gollub, Dr.P.H., 2/91

* Thesis examination committees (Epidemiology)

S. Garbers, Ph.D, 2011

D. Maine, Dr.P.H, 6/98 (chair)

M. Latka, 7/97 (chair)

L. Samelson, 4/97 (chair)

J. Jacobson, Ph.D, 6/95 (chair)

X. Shu, Ph.D, 6/93

P. Murphy, Dr.P.H, 6/93

J. Sackoff, Ph.D, 5/92

* Master's degree student advisor (MPH or MS, Epidemiology)

T Jain (2019)

M. Tiedeken (2018)

C. Ndubisi (2018)

A. Fu (2017)

C. Weber (2017)

C. Basaraba (2016)

K. Rivlin (2015)

NT. Ohly (2014)

K. Morrell (2012)

K. Maguire (2011)

M. Guiahi (2011)

A. Siddiqui (2011)

A. Beasley (2010)

J. Guerrero (2010)

N. Shimoni (2009)

A. Langston (2009)

E.R. Mayeda (2009)

M. Dragoman (2008)

A. Dempsey (2008)

C. Estes (2007)

C. Galvao (2007)

L. Rosenblatt (2006)

C. Robilotto (2006)

A.G. Thomas (Mt. Sinai School of Medicine)

M. Minguez (Mt. Sinai School of Medicine)

Y. Swica (2006)

R. Sneed (2005)

J. Shafer (2005)

S. Kaufman-Hendlish (2005)

P. Castano (2005)

K. O’Connell (2004)

K. Petrie (2012)

C. Morroni (University of Capetown) (2003)

S. Teal (2003)

L. De Nonno (2000)

A. Davis (1999)

M. Jacobs (1999)

N. New (1997)

P. Murphy (1993)

M.C. Randall (1992)

* Master's degree student advisor (MPH Pop Fam and Biostatistics)

B. Kumar (2015)

S. Nippita (2013)

S. Joslin-Roher (2012)

A. Torgal (2010)

E. Pressman (2009)

I. Holloway (2008)

M Tepe (2007)

D. Horowitz (2005)

* Master’s degree student advisor (Institute of Human Nutrition)

R. Tang (2014)

D. Li (2013)

13) **Publications**

## A. *Peer Reviewed Research Publications or Other Media*

## *Under Review*

## Burke A, Murthy A, Chen B, Muraguri GR, Jensen JT, Kimble TD, Schreiber AC, Dart C, Westhoff CL, Blithe DL. Contraceptive efficacy and safety of the Woman’s Condom: Results from a phase III, open-label, multicenter trial. Contraception.

## Chen M, Creinin MD, Turok DK, Archer DF, Barnhart KT, Westhoff CL, Thomas MA, Jensen JT, Variano BV, Sitruk-Ware R, Shanker A, Long J, Blithe DL. Dose-finding study of a 90-day contraceptive vaginal ring releasing estradiol and segesterone acetate. Contraception.

## *Accepted/In-Press*

1. Spotnitz ME, Natarajan K, Ryan PB, **Westhoff CL**. Relative risk of cervical neoplasms among copper and levonorgestrel intrauterine device users. Obstet and Gynecol. Accepted.
2. Vieira CS, Fraser IS, Plagianos MG, Burke AE, **Westhoff CL**, Jensen J, Brache V, Bahamondes L, Merkatz RB, Sitruk-Ware R, Blithe DL. Bleeding profile associated with 1-year use of the segestreone acetate/ethinyl estradiol contraceptive vaginal system: pooled analysis from phase 3 trials. Contraception. In press. [https://doi.org/10.1016/j.contraception.2019.07.145](https://urldefense.proofpoint.com/v2/url?u=https-3A__protect-2Dus.mimecast.com_s_vAPxC5yl0guZWD8GuzQQ39-3Fdomain-3Ddoi.org&d=DwMGaQ&c=G2MiLlal7SXE3PeSnG8W6_JBU6FcdVjSsBSbw6gcR0U&r=Jq2sjiyYiBbwL6jG0foMGO-yzziDSwP-ao_rGoqDsIA&m=qbnvEBm4idFC_9T-ZYJ01JFeQWJBGFfVG5Gqkcn-0VA&s=kYyM5SzIR--zi7IrxwrUCWfxbOnnJbcZgQP5BD9lj2Y&e=) PMID: 31398307
3. Teodoro N, Fu A, Ohly T, Shalev N, Matseoane-Peterssen D, **Westhoff CL**. Long-acting reversible contraception knowledge, attitudes, and use among HIV-infected and uninfected women and their providers. Contraception. In press. <https://doi.org/10.1016/j.contraception.2019.06.005> PMID: 31226320

*Published*

1. Chen BA, Blithe DL, Muraguri GR, Lance AA, Carr BR, Jensen JT, Kimble TD, Murthy AS, Schreiber CA, Thomas MA, Walsh TL, **Westhoff C**, Burke AE. Acceptability of the Woman’s Condom in a phase III multicenter open-label study. Contraception. 2019 Jun 99(6):357-362. PMID 30849305
2. Tiedeken M, **Westhoff CL**, Cohen A, Cremers S, Sitruk-Ware R, Blithe DL, The NICHD Contraceptive Trials Network Vaginal Ring Group. Bone turnover markers in women participating in a dose-finding trial of a contraceptive vaginal ring releasing Nestorone and estradiol. Contraception. 2019 Jun 99(6):329-334. PMID 30871934
3. Luo D, **Westhoff CL**, Edelman AB, Natavio M, Stanczyk FZ, Jusko WJ. Altered pharmacokinetics of combined oral contraceptives in obesity—multistudy assessment. Contraception. 2019 Apr 99(4): 256-263. PMID 30684471
4. Rivlin K, **Westhoff CL**. Navigating uncertainty: Narrative Medicine in pregnancy options counseling education**.** Patient Educ Couns. 2019 Mar 102(3):536-541. PMID 30385101
5. Ndubisi C, Danvers A, Gold MA, Morrow L, **Westhoff CL**. Auricular acupuncture as an adjunct for pain management during first trimester abortion: a randomized, double-blinded, three arm trial. Contraception. 2019 99:143-147. PMID 30529393
6. **Westhoff CL,** Pike MC.Hormonal contraception and breast cancer.Contraception. 2018 Sep 98(3):171-173. PMID 30193687
7. Fu A, Weber CE, Gilmore E, Davis A, Hirsch G, **Westhoff CL**. A non-inferiority randomized controlled trial to compare transabdominal and transvaginal sonography for eligibility assessment prior to medical abortion. Contraception. 2018 Sep 98(3):199-204. PMID 29752922
8. Garbers S, Bell DL, Ogaye K, Marcell AV, **Westhoff CL**, Rosenthal SL. Advance Provision of Emergency Contraception to Young Men: An Exploratory Study in a Clinic Setting. Contraception. 2018 Aug 98(2):106-109. PMID 29678366
9. Steinberg JR, Adler NE, Thompson KM, **Westhoff C**, Harper CC. Current and past depressive symptoms and contraceptive effectiveness method selected among women seeking reproductive health services. Social Science & Medicine. 2018 Aug 13;214:20-25. PMID: 30138841
10. **Westhoff CL**, Pike MC. Hormonal contraception and breast cancer. Am J Obstet Gynecol. 2018 Aug 219(2):169. PMID 29779566
11. **Westhoff CL**, Chen BA, Jensen JT, Barnhart K, Thomas M, Teal S, Blithe D. Phase I/II pharmacokinetic and pharmacodynamic evaluation of two levonorgestrel-only contraceptive patches in a multicenter randomized trial. Contraception. 2018 Apr 98(2):151-157. PMID 29679590
12. Kohn JE, Simons HR, Della Badia L, Draper E, Morfesis J, Talmont E, Beasley A, McDonald M, **Westhoff CL**. Increased one-year continuation of DMPA among women randomized to self-administration: results from a randomized controlled trial at Planned Parenthood. Contraception. 97 (2018):198-204. PMID 29246818
13. Jensen JT, Edelman AB, Chen BA, Archer DF, Barnhart KT, Thomas MA, Burke AE, **Westhoff CL**, Wan LS, Siturk-Ware R, Kumar N, Bariano B, Blithe DL. Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study. Contraception 97(2018):422-427. PMID 29409834

1. Stockwell MS, Wu M, Castaño PM, Schnall R, **Westhoff CL**, Santelli J, Dayan PS. Texting to Increase Contraceptive Use Among Adolescents in the Emergency Department: A Pilot Randomized Controlled Trial. Journal of Adolescent Health. 2017;61(6): 786-90. PMID 29056437
2. Chernick LS, Schnall R, Stockwell MS, Castano PM, Higgins T, **Westhoff C**, Santelli J, Dayan PS. Adolescent female text messaging preferences to prevent pregnancy after an emergency department visit: A qualitative analysis. J Med Internet Res. 2016;18:e261. PMID 29056437
3. Nandakumar R, Praditpan P, **Westhoff CL**, Cremers S. A UPLC-MS/MS method for the quantitation of ulipristal acetate in human serum. Journal of Chromatography B. 2017 May 24. PMID: 28570936
4. Raymond E, Blanchard K, Blumenthal P, Cleland K, Foster A, Gold M, Grossman D, Pendergast M, **Westhoff C**, Winikoff B. Sixteen Years of Overregulation: Time to Unburden Mifeprex®. New England Journal of Medicine. 2017 Feb 23; PMID: 28225670
5. Morroni C, Findley M, **Westhoff C**. Does using the “Pregnancy Checklist”

 delay safe initiation of contraception? Contraception. 2017 Jan 25; PMID:

 28131649

1. Praditpan P, Hamouie A, Basaraba CN, Nandakumar R, Cremers S,

 Davis AR, **Westhoff CL**. Pharmacokinetics of levonorgestrel and ulipristal

 acetate emergency contraception in women with normal and obese body

 mass index. Contraception. 2017 Jan 23; PMID: 28126541

1. **Westhoff CL**, Pike MC, Cremers S, Eisenberger A, Thomassen S, Rosing

J. Endogenous thrombin potential changes during the first cycle of oral

 contraceptive use. Contraception. 2017 Jan 11. 95(5): 456-463. PMID: 28088496

1. Mansour D, **Westhoff C**, Kher U, Korver T. Pooled analysis of two randomized, open-label studies comparing the effects of nomegestrol acetate/17β-estradiol and drospirenone/ethinyl estradiol on bleeding patterns in healthy women. Contraception. 2016 Dec 12; PMID: 28011288
2. Basaraba CN, **Westhoff CL**, Pike MC, Nandakumar R, Cremers S.

 Estimating systemic exposure to levonorgestrel from an oral contraceptive.

 Contraception. 2016 Dec 30. PMID: 28041990

1. White K, Nucatola D, **Westhoff C**. Intra-fetal Compared with Intra-amniotic Digoxin Prior to Dilation and Evacuation: A Randomized Controlled Trial. Obstet Gynecol. 2016 Nov; 128(5):1071-1076. PMID: 27741192
2. Chernick LS, Schnall R, Stockwell MS, Castano PM, Higgins T, **Westhoff C**, Santelli J, Dayan PS. Adolescent female text messaging preferences to prevent pregnancy after an emergency department visit: A qualitative analysis. J Med Int Res. 2016 Sep 29; 18(9):e261. PMID: 27687855
3. Aiken A, **Westhoff C**, Castano P, Trussel J. Comparison of a Timing-Based Measure of Unintended Pregnancy and the London Measure of Unplanned Pregnancy. Perspect Sex Reprod Health. 2016 Sep; 48(3):139-46. PMID: 27574959
4. Morrell K, Cremers S, **WESTHOFF CL**, Davis AR. Relationship between etonogestrel level and BMI in women using the contraceptive implant for more than one 1 year. Contraception 2016 Mar; 93(3):263-5. PMID: 26577754
5. **WESTHOFF CL**, Eisenberger A, Tang R, Cremers S, Grossman LV, Pike MC. Clotting factor changes during the first cycle of oral contraceptive use. Contraception 2016; 93(1):70-6. PMID: 26452328
6. **WESTHOFF CL**, Yoon LS, Tang R, Pulido V, Eisenberger A. Risk factors for venous thromboembolism among reproductive age women. J Women’s Health 2016; 25(1):63-69. PMID: 26317174
7. Rocca CH, Thompson KM, Goodman S, **WESTHOFF CL**, Harper CC. Funding policies and post-abortion long-acting reversible contraception: Results from a cluster randomized trial. Am J Obstet Gynecol. 2016 Jun;214(6):716.e1-8. PMID: 26692178
8. Nippita S, Oviedo JD, Velasco MG, **WESTHOFF CL**, DAVIS AR, Castano PM. A randomized controlled trial of daily text messages versus monthly paper diaries to collect bleeding data after intrauterine device insertion. Contraception 2015; 92(6):578-84 PMID: 26363433
9. \* Maguire K, DAVIS AR, Joslin-Roher S, **WESTHOFF CL**. IUDs at 1 year: Predictors of early discontinuation. Contraception 2015; 92(6):575-7. PMID: 26365791
10. \* Brinton LA, Moghissi KS, Scoccia B, Lamb EJ, Trabert B, Niwa S, Ruggieri D, **WESTHOFF CL.** Effects of fertility drugs on cancers other than breast and gynecologic malignancies. Fertil Steril 2015; 104(4):980-8. PMID: 26232746
11. Morrell K, **WESTHOFF CL**, Castano, PM. The relationship between neighborhood-level poverty assessed with geocoding and oral contraceptive continuation. Clin Obstet Gynecol Reprod Med 2015; (2):51-54. No PubMed ID
12. \* Harper CC, Rocca CH, Thompson KMJ, Morfesis J, Goodman S, Darney PD, Speidel JJ, **WESTHOFF CL.** Reductions in pregnancy rates in the USA with long-acting reversible contraception: a cluster randomized trial. The Lancet 2015; 386(9993): 562-8. PMID: 26091743
13. Eisenberg DL, Schreiber CA, Turok DK, Teal SB, **WESTHOFF CL**, Creinin MD. Three-year efficacy and safety of a new 52-mg levonogestrel-releasing intrauterine system. Contraception 2015; 92(1):10-6. PMID: 25934164
14. \* Myers J, Ellman T, **WESTHOFF CL.** Injectable agents for pre-exposure prophylaxis: Lessons learned from contraception to inform HIV prevention. Curr Opin HIV/AIDS 2015; 10(4):271-7. PMID: 26049953

1. **WESTHOFF CL,** Pike MC, Tang R, DiNapoli MN, Sull M, Cremers S. Estimating systemic exposure to ethinyl estradiol from an oral contraceptive. Am J Obstet Gynecol 2015; 212(5):614.e1-7 PMID: 25511238
2. Chernick LS, **WESTHOFF CL**, Ray M, Garcia M, Garth J, Santelli J, Dayan PS. Enhanced referral of sexually active adolescent females from the emergency department to family planning. J Womens Health 2015; 24(4):324-8. PMID: 25860108
3. Kaunitz AM, Portman D, **WESTHOFF CL**, Archer DF, Mishell D, Foegh M. Self-reported and verified compliance in a Phase 3 clinical trial of a novel low-dose contraceptive patch and pill. Contraception 2015; 91(3):204-10. PMID: 25582984
4. Kaunitz AM, Portman D, **WESTHOFF CL**, Mishell D, Archer DF, Foegh M. New contraceptive patch wearability assessed by investigators and participants in a randomized phase 3 study. Contraception 2015; 91(3):211-6. PMID: 25586864
5. **WESTHOFF CL**, Reinecke I, Bangerter K, Merz M. Impact of body mass index on suppression of follicular development and ovulation using a transdermal patch containing 0.55 mg ethinyl estradiol/2.1 mg gestodene: A multicenter, open-label, uncontrolled study over three treatment cycles. Contraception 2014; 90(3):272-9. PMID: 24969733
6. \* Hall KS, Castaño PM, **WESTHOFF CL**. The Influence of oral contraceptive knowledge on oral contraceptive continuation among young women. J Womens Health 2014;23(7):596-601 PMID: 24571282
7. \* Eisenberger A, **WESTHOFF CL**. Hormone replacement therapy and venous thromboembolism. J Steroid Biochem Mol Biol 2014; 142C:76-82. PMID: 24007716
8. \* Morroni C, Heartwell S, Edwards S, Zieman M, **WESTHOFF CL**. The impact of oral contraceptive initiation on young women's condom use: missed opportunities for intervention. PLoS One 2014; 9(7):e101804. PMID: 25003504
9. \* Harrison MS, DiNapoli MN, **WESTHOFF CL**. Reducing postoperative pain after tubal ligation with rings or clips: A systematic review and meta-analysis. Obstet Gynecol 2014; 124(1):68-75. PMID: 24901271
10. \* Beasley A, White KO, Cremers S, **WESTHOFF CL**. Randomized clinical trial of self versus clinical administration of subcutaneous depo medroxyprogesterone acetate. Contraception 2014; 89(5):352-6. PMID: 24656555
11. \* Shimoni N, Davis A, **WESTHOFF CL**. Can ultrasound predict IUD expulsion after medical abortion? Contraception 2014; 89(5):434-9. PMID: 24560483
12. Brinton LA, **WESTHOFF CL**, Scoccia B, Lamb EJ,Trabert B, Niwa S, Moghissi KS. Long-term relationship of ovulation-stimulating drugs to breast cancer risk. Cancer Epidemiol Biomarkers Prev 2014; 23(4):584-93. PMID: 2700523
13. Stockwell MS, **WESTHOFF CL**, Kharbanda EO, Vargas C, Stewin C, Vawdrey DK, Castaño PM. Influenza vaccine text message reminders for urban, low-income pregnant women: A randomized controlled trial. Am J Public Health 2014; 104 (Suppl) 1:e7-12. PMID: 24354839
14. Kaunitz AM, Portman D, **WESTHOFF CL**, Archer DF, Mishell DR, Rubin A, Foegh M. Low-Dose Levonorgestrel and Ethinyl Estradiol Patch and Pill: A Randomized Controlled Trial. Obstet Gynecol 2014; 123(2 Pt 1):295-303. PMID: 24402597
15. \* Langston AM, Joslin-Roher SL**, Westhoff CL**. Immediate post-abortion access to IUDs, implants and DMPA reduces repeat pregnancy within 1 year in a New York City practice. Contraception 2014; 89(2):103-8. *Winner of NYC’s DOHMH Most Impactful Article of 2013 Award.*

PMID: 24309218

1. Mayeda ER, **WESTHOFF CL**, Torgal A. Weight and body composition changes during oral contraceptive use in obese and normal weight women. J Womens Health 2014; 23(1):38-43. PMID: 24156617
2. Maguire K, Morrell K, **WESTHOFF CL**, Davis A. Accuracy of providers’ assessment of pain during intrauterine device insertion. Contraception 2014; 89(1):22-4. PMID: 24134898
3. \* Jones HE, Mansukhani MM, Tong GX, **WESTHOFF CL**. Validity and reliability of using a self-lavaging device for cytology and HPV testing for cervical cancer screening: Findings from a pilot study. PLoS One 2013; 8(12):e82115 PMID: 24376516
4. Thomas T, Petrie K, Shim J, Abildskov KM, **WESTHOFF CL**, Cremers S. A UPLC-MS/MS method for therapeutic drug monitoring of Etonogestrel. Ther Drug Monit 2013; 35(6):844-8. PMID: 24081205
5. Trabert B, Lamb EJ, Scoccia B, Moghissi KS, **WESTHOFF CL**, Niwa S, Brinton LA. Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large U.S. infertility cohort. Fertil Steril 2013; 100(6):1660-6. PMID: 24011610
6. Keyes KM, Cheslack-Postava K**, WESTHOFF CL**, Heim CM, Haloossim M, Walsh K, Koenen K. Association of hormonal contraceptive use with reduced levels of depressive symptoms: a national study of sexually active women in the United States. Am J Epidemiol 2013;178 (9): 1378-1388. PMID: 24043440
7. Brinton LA, **WESTHOFF CL**, Scoccia B, Lamb EJ,Trabert B, Niwa S, Moghissi KS. Fertility drugs and endometrial cancer risk: Results from an extended follow-up of a large infertility cohort. Hum Reprod 2013; 28(10): 2813-21. PMID: 23943795
8. \* Jones HE, Holloway IW, Pressman E, Meier J, **WESTHOFF CL**. Women’s preferences for testing and management of sexually transmitted infections among low-income New York City family planning clients. Int J STD AIDS 2013; 24(6): 455-60. PMID: 23970748
9. Guiahi M, **WESTHOFF CL**, Summers S, Kenton K. Training at a faith-based institution matters for Obstetrics and Gynecology residents: Results from a regional survey. J Grad Med Educ 2013; 5(2):244-51. PMID: 24404267
10. \* Guiahi M, Lim S, Westover C, Gold M, **WESTHOFF CL**. Enablers of and barriers to abortion training. J Grad Med Educ 2013; 5(2):238-43. PMID: 24404266
11. Lopez LM, Grimes DA, Chen M, Otterness C, **WESTHOFF CL**, Edelman A, Helmerhorst FM. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Library 2013, Issue 4 Art. No: CD008452. PMID: 23633356
12. \* Dragoman M, Petrie K, Torgal A, Thomas T, Cremers S, **WESTHOFF CL**. Contraceptive vaginal ring effectiveness is maintained during six weeks use: A prospective study of normal BMI and obese women. Contraception 2013; 87(4):432-6. PMID: 23312933
13. \* Hall K, Castaño PM, **WESTHOFF CL**. The impact of an educational text message intervention on young urban women's knowledge of oral contraception. Contraception 2013; 87(4):449-54. PMID: 23062523
14. **WESTHOFF CL**, Petrie KA, Cremers S. Using changes in binding globulins to assess oral contraceptive compliance. Contraception 2013; 87(2):176-81. PMID: 22795088
15. \* Hall KS, White KO, Rickert VI, Reame NK, **WESTHOFF CL**. An exploratory analysis of associations between eating disordered symptoms, perceived weight changes, and oral contraceptive discontinuation among young minority women. J Adolesc Health 2013; 52(1):58-63. PMID: 23260835
16. \* Jones HE, Brudney K, Sawo DJ, Lantigua R, **WESTHOFF CL**. The acceptability of a self-lavaging device compared to pelvic examination for cervical cancer screening among low-income women. J Womens Health 2012; 21(12):1275-81. PMID: 22906043
17. \* Hall KS, White KO, Rickert VI, Reame N, **WESTHOFF CL**. Influence of depressed mood and psychological stress symptoms on perceived oral contraceptive side effects and discontinuation in young minority women. Contraception 2012; 86(5):518-25. PMID: 22673038
18. \* Guiahi M, Westover C, Lim S, **WESTHOFF CL**. The New York City mayoral abortion training initiative at public hospitals. Contraception 2012; 86(5):577-82. PMID: 22464409
19. \* Maguire K, Davis A, Rosario Tejeda L, **WESTHOFF CL**. Intracervical lidocaine gel for intrauterine device insertion: a randomized controlled trial. Contraception 2012; 86(3):214-9. PMID: 22325115
20. \* Guerrero JM, Castaño PM, Schmidt EO, Rosario L, **WESTHOFF CL**. Music as an auxiliary analgesic during first trimester surgical abortion: a randomized controlled trial. Contraception 2012; 86(2):157-62. PMID: 22240180
21. **WESTHOFF CL**, Torgal AH, Mayeda ER, Petrie K, Thomas T, Dragoman M, Cremers S. Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women. Am J Obstet Gynecol 2012; 207(1):39.e1-6. PMID: 22727346
22. **WESTHOFF CL**, Kaunitz A, Korver T, Sommer W, Bahamondes L, Darney P, Verhoeven C. Efficacy, safety, and tolerability of a monophasic oral contraceptive containing Nomegestrol Acetate and 17B-Estradiol. Obstet Gynecol 2012; 119(5):989-999. PMID: 22525910
23. **WESTHOFF CL**, Torgal AT, Mayeda ER, Shimoni N, Stanczyk FZ, Pike MC. Predictors of noncompliance in an oral contraceptive clinical trial. Contraception 2012; 85(5):465-9. PMID: 22079603
24. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS; PLCO Project Team (**WESTHOFF CL**). Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012; 104(2):125-32. PMID: 19297565
25. \* Beasley A, Estes C, Guerrero J, **WESTHOFF CL**. The effect of obesity and low-dose oral contraceptives on carbohydrate and lipid metabolism. Contraception 2012; 85(5):446-52. PMID: 22078632
26. **WESTHOFF CL**, Hait HI, Reape KZ. Body weight does not impact pregnancy rates during use of a low-dose extended-regimen 91-day oral contraceptive. Contraception 2012; 85(3):235-9. PMID: 22067763
27. \* Castaño PM, Bynum JY, Andrés R, Lara M, **WESTHOFF CL**. Effect of daily text messages on oral contraceptive continuation: a randomized controlled trial. Obstet Gynecol 2012; 119(1):14-20. PMID: 22067763
28. \* Petrie K, **WESTHOFF CL.** Matched-pairs analysis of ovarian suppression during oral versus vaginal hormonal contraceptive use. Contraception 2011; 84(5):e1-4. PMID: 22018131
29. \* Jones HE, Pressman EJ, Bell DL, Kerns JL, Lykes ST, Garth J, **WESTHOFF CL**. Managing chlamydia infections in young men: Results from an audit of a public men's clinic in New York City. Int J STD AIDS 2011; 22(10):581-4. PMID: 21998179
30. \* White KO, **WESTHOFF CL.** The effect of pack supply on oral contraceptive pill continuation: A randomized controlled trial. Obstet Gynecol 2011; 118(3):615-22. PMID: 21860291
31. Shimoni N, Davis A, Ramos ME, Rosario L, **WESTHOFF C.** Timing of copper intrauterine device insertion after medical abortion: a randomized controlled trial. Obstet Gynecol 2011; 118(3):623-8. PMID: 21860292
32. \* Kerns J, Jones HE, Pressman E, Fratarelli LA, Garth J, **WESTHOFF CL**. Implementation of expedited partner therapy among women with chlamydia infection at an urban family planning clinic. Sex Transm Dis 2011; 38(8):722-6. PMID: 21844724
33. Buys SS, Partridge E, Black A, Johnson CC; PLCO Project Team (**WESTHOFF CL**). Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011; 305(22):2295-303. PMID: 21642681
34. \* Dempsey AR, Johnson SS, **WESTHOFF CL**. Predicting oral contraceptive continuation using the trans-theoretical model of health behavior change. Perspect Sex Reprod Health 2011; 43(1): 23-29. PMID: 21388502
35. **WESTHOFF CL**, Jones HE, Guiahi M. Do new guidelines and technology make the routine pelvic examination obsolete? J Womens Health 2011; 20(1):5-10. PMID: 21194307
36. \* Hall KS, Castaño PM, Stone PW, **WESTHOFF C**L. Measuring oral contraceptive knowledge: a review of research findings and limitations. Patient Educ Couns 2010; 81(3):388-94. PMID: 21034277
37. Lopez LM, Grimes DA, Chen-Mok M, **WESTHOFF CL**, Edelman A, Helmerhorst FM. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev. 2010; (7): CD008452. Review. PMID: 20614470
38. \* Chan LM, **WESTHOFF CL**. Tubal sterilization trends in the United States. Fertil Steril 2010; 94(1):1-6. PMID: 20497790
39. Davis A, **WESTHOFF CL**, Stanczyk F. Carbamazepine co-administration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. Epilepsia 2010; 52(2):243-7. PMID: 21204827
40. \* Holloway, IW, Jones HE, Bell DL, **WESTHOFF CL**. Men’s preferences for sexually transmitted infection care services in a low-Income community clinic setting in New York City. Am J Mens Health 2010; 5(3):208-15. PMID: 20483869
41. Burke AE, Barnhart K, Jensen JT, Creinin MD, Walsh TL, Wan LS, **WESTHOFF CL**, Thomas M, Archer D, Wu H, Liu J, Schlaff W, Carr BR, Blithe D. Contraceptive efficacy, acceptability, and safety of C31G and nonoxynol-9 spermicidal gels: a randomized controlled trial. Obstet Gynecol 2010; 116(6):1265-1273. PMID: 21099590
42. \* Langston AM, Rosario L, **WESTHOFF CL**. Structured contraceptive counseling--a randomized controlled trial. Patient Educ Couns 2010; 81(3):362-7. PMID: 20869187
43. \* Hall K, Reame N, O’Connell K, **WESTHOFF CL**. Studying the use of oral contraception: A review of measurement approaches. J Womens Health 2010; 19(12):2203-2210. PMID: 21084170
44. Brinton L, Moghissi K, **WESTHOFF CL**, Lamb E, Scoccia B. Cancer risk among infertile women with androgen excess or menstrual disorders (including polycystic ovary syndrome). Fertil Steril 2010; 94:1787-92. PMID: 19939368
45. \* Dempsey A, Roca C, **WESTHOFF CL**. Vaginal estrogen supplementation during Depo Provera initiation. Contraception 2010; 82(3):250-255. PMID: 20705153
46. **WESTHOFF CL**, Torgal A, Mayeda ER, Stanczyk F, Lerner JP, Benn EKT, Paik M. Ovarian suppression in obese and normal weight women during oral contraceptive use. Obstet Gynecol 2010; 116(2):275-283. PMID: 20664386
47. **WESTHOFF CL**, Torgal A, Mayeda ER, Pike M, Stanczyk F. Pharmacokinetics of a combined oral contraceptive in obese and normal weight women. Contraception 2010;81(6):474-80. PMID: 20472113
48. \* Dinger JC, Cronin M, Möhner S, Schellschmidt I, Do Minh T, **WESTHOFF CL**. Oral contraceptive effectiveness according to body mass index, weight, age, and other factors. Am J Obstet Gynecol 2009; 201(3):263-266. PMID: 19481720
49. \* Swica Y, **WESTHOFF CL**. Comparison of serum markers for thromborphilia and autoimmune disease in reproductive age women with and without false positive rapid plasma reagin tests. Am J Reprod Immunol 2009; 62(2):73-7. PMID: 19614623
50. \* Soren K, Kharbanda E, Chen S, **WESTHOFF CL**. A six year experience with pap smears in an urban adolescent practice: the scope and burden of abnormalities. J Pediatr Adolesc Gynecol 2009; 22(4):217-22. PMID: 19646666
51. **WESTHOFF CL**, Jones K, Robilotto C, Heartwell S, Edwards S, Zieman M, Cushman L. Smoking and oral contraceptive continuation. Contraception 2009; 79(5):375-8. PMID: 19341850
52. PLCO Project Team. **(WESTHOFF CL)** Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360 (13):1310-9. PMID: 19297565
53. \* Teal S, Harken T, Sheeder J, **WESTHOFF CL**. Efficacy, acceptability and safety of medication abortion in low-income, urban Latina women. Contraception 2009; 80(5):479-483. PMID: 19835724
54. \* Madden T, **WESTHOFF CL**. Rates and follow-up and repeat pregnancy in the 12 months after first-trimester induced abortion. Obstet Gynecol 2009; 113(3):663-668. PMID: 19300332
55. \* Wiegerinck MM, Jones HE, O’Connell K, Lichtenberg ES, Paul M, **WESTHOFF CL**. Medical abortion practices: A survey of national abortion federation members in the United States. Contraception 2008; 78(6):486-91. PMID: 19014795
56. \* Jones HE, Wiegerinck HM, Nieboer TW, Mol BW, **WESTHOFF CL.** Women in the Netherlands prefer self-sampling with a novel lavaging device to clinician collection of specimens for cervical cancer screening. Sex Transm Dis 2008; 35(11):916-7. PMID: 18665020
57. Creinin M, Meyn L, Borgatta L, Barnhart K, Jensen J, Burke A, **WESTHOFF CL,** Gilliam M, Dutton C. A randomized, multi-center comparison of the contraceptive ring and patch. Obstet Gynecol 2008; 11(2)267-277. PMID: 18238962
58. \* Edwards SM, Zieman M, Jones K, Diaz A, Robilotto C, **WESTHOFF CL**. Initiation of oral contraceptives – Start now! J Adolesc Health 2008; 43(5):432-6. PMID: 18848670
59. Nelson AL, **WESTHOFF CL**, Schnare SM. Real-world patterns of prescription refills for branded hormonal contraceptives: A reflection of contraceptive discontinuation. Obstet Gynecol 2008; 112(4):782-7. PMID: 18827120
60. Kalmuss D, Koenemann S, **WESTHOFF CL**, Heartwell S, Edwards S, Zieman M, Cushman L, Robilotto C, Stuart G. Prior pill experiences and current continuation among pill restarters. Perspect Sex Repro Health 2008; 40(3):138–143. PMID: 18803795
61. Chen B, Reeves MF, Gilles JM, Barnhart K, **WESTHOFF CL**, Zhang J. National Institute of Child Health and Human Development, Management of early pregnancy failure trial, misoprostol for treatment of early pregnancy failure in women with previous uterine surgery. Am J Obstet Gynecol 2008; 198(6):626.e1-5. PMID: 18279821
62. \* Estes C, Ramierez J, Tiezzi L, **WESTHOFF CL**. Self-pregnancy testing in an urban family planning clinic: Promising results for a new Approach to contraceptive follow-up. Contraception 2008; 77(1):40-43. PMID: 18082665
63. Molaei M, Jones H, **WESTHOFF CL**. Effectiveness and safety of digoxin to induce fetal demise prior to second trimester abortion. Contraception 2008; 77(5):315-388. PMID: 18279695
64. \* Stuart G., **WESTHOFF CL**. A high cholecystectomy rate in a cohort of women who are Mexican-American, and postpartum, at the time of oral contraceptive pill initiation. Contraception 2007; 76:357-359. PMID: 17963859
65. Robledo C, Zhang J, Troendle J, Barnhart K, Creinin C, **WESTHOFF CL**, Huang X, Frederick M. Clinical indicators for success of misoprostol treatment after early pregnancy failure. Int J Gynaecol Obstet 2007; 99: 46-5. PMID: 17599843
66. Westhoff CL, Heartwell S, Edwards S, Zieman M, Stuart G, Cwiak C, Davis A, Robilotto T, Cushman L, Kalmuss D. Oral contraceptive discontinuation: do side effects matter? Am J Obstet Gynecol 2007; 196:412.e1-412e7.
67. Barnhart K, Rosenberg M, MacKay T, Blithe D, Higgins J, Walsh T, Wan L, Thomas M, Creinin M, **WESTHOFF CL**, Schlaff W, Archer D, Ayers C, Kaunitz A, Das S, Moench T. Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm. Obstet Gynecol 2007; 110:577-586. PMID: 17766603
68. **WESTHOFF CL**, Jain JK, Milsom I, Ray A. Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL. Contraception 2007; 75:261-267. PMID: 17362703
69. \***Westhoff C**, Heartwell S, Edwards S, Zieman M, Cushman L, Robilotto C, Stuart G, Morroni C, Kalmuss D**.** Initiation of oral contraceptives: A randomized trial of quick start versus conventional start. Obstet Gynecol 2007; 109:1270-1276. PMID: 17540797
70. \* Teal SB, Dempsey-Fanning A, **WESTHOFF CL**. Predictors of acceptability of medication abortion. Contraception 2007; 75:224-9. PMID: 17303494
71. \* Rickert VI, Tiezzi L, Lipshutz J, Leon J, Vaughan RD, **WESTHOFF CL**. Depo now: Preventing unintended pregnancies among adolescents and young adults. J Adolesc Health 2007; 40(1):22-8. PMID: 17185202
72. Davis AR, Hendlish SK, **WESTHOFF CL**, Frederick MM, Zhang J, Gilles JM, Barnhart K, Creinin MD. Bleeding patterns after medical management of miscarriage. Am J Obstet Gynecol 2007; 196:31e1-31e7. PMID: 17240222
73. Mishell DR, Guillebaud J, **WESTHOFF CL**, Nelson AL, Kaunitz AM, Trussell J, Davis AJ. Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials. Contraception 2007; 75(1):11-15. PMID: 17161117
74. Mishell DR, Guillebaud J, **WESTHOFF CL**, Nelson AL, Kaunitz AM, Trussell J, Davis AJ. Combined oral contraceptives: Variable data collection and bleeding assessment methodologies influence study outcomes and physician perception. Contraception 2007; 75(1):4-10. PMID: 17161116
75. \* Davis AR, Osborne LM, O’Connell KJ, **WESTHOFF CL**. Challenges of conducting a placebo-controlled trial for dysmenorrhea in adolescents. J Adolesc Health 2006; 39(4):607-9. PMID: 16982402
76. \* O'Connell K, Davis, AR, **WESTHOFF CL**. Self-treatment patterns among adolescent girls with dysmenorrhea. J Pediatr Adolesc Gynecol 2006; 19:285-89. PMID: 16873033
77. Fogle RH, Murphy PA, **WESTHOFF CL**, Stanczyk F. Does St. John's Wort interfere with the antiandrogenic effect of oral contraceptive pills? Contraception 2006; 74(3):245-8. PMID: 16904419
78. Creinin M, Huang X, **WESTHOFF CL**, Barnhart K, Gilles J, Zhang J. Factors related to successful misoprostol treatment for early pregnancy failure. Obstet Gynecol 2006; 107(4):901-7. PMID: 16582130
79. \* Gentile GP, Helbig D, Zacur H, Park T, Lee Y, **WESTHOFF CL**. Hormone levels in women before and after tubal sterilization. Contraception 2006; 73(5):507-11. PMID: 16627035
80. Shulman LP, Bateman LH, Creinin MD, Cullins VE, Doyle LL, Godfrey E, Murphy P, Rodriguez P, Spear SJ, Stewart FH, Thomas MA, **WESTHOFF CL**, Worthington S. Surrogate markers, emboldened and boxed warnings, and an expanding culture of misinformation: evidence-based clinical science should guide FDA decision making about product labeling. Contraception 2006; 73(5):440-2. PMID: 16627028
81. Davis AR, **WESTHOFF CL**, O'Connell K, Gallagher N. Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial. Obstet Gynecol 2005; 106:97-104. PMID: 15994623
82. Sonnenberg FA, Burkman RT, Speroff L, **WESTHOFF CL**, Hagerty CG. Cost-effectiveness and contraceptive effectiveness of the transdermal contraceptive patch. Am J Obstet Gynecol 2005; 192(1):1-9. PMID: 15671994
83. Stewart FH, Kaunitz AM, LaGuardia KD, Karvois DL, Fisher AC, Friedman AJ, **WESTHOFF CL**, and the Ortho Evra Extended Regimen Study Group. Extended use of transdermal norelgestromin/ethinyl estradiaol: A randomized trial. Obstet Gynecol 2005; 105:1389-1396. PMID: 15932834
84. \* O’Connell K, Osborne LM, **WESTHOFF CL**. Measured and reported weight change for women using a vaginal contraceptive ring versus a low-dose oral contraceptive. Contraception 2005; 72:323-327. PMID: 16246655
85. **WESTHOFF CL**, Osborne L, Schafer J, Morroni C. Bleeding patterns after immediate initiation of the contraceptive pill and vaginal ring. Obstet and Gynecol 2005; 106:89-96. PMID: 15994622
86. Althuis MD, Scoccia B, Lamb EJ, Moghissi KS, **WESTHOFF CL**, Mabie JE, Brinton LA. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. Am J Obstet Gynecol 2005; 193:668-74. PMID: 15781949
87. Zhang J, Gilles JM, Barnhart K, Creinin MD, **WESTHOFF CL**, Frederick MM; National Institute of Child Health Human Development (NICHD) Management of Early Pregnancy Failure Trial. A comparison of medical management with misoprostol and surgical management for early pregnancy failure. N Engl J Med 2005; 353(8):761-9. PMID: 16120856
88. Althuis MD, Moghissi KS, **WESTHOFF CL**, Scoccia B, Lamb EJ, Lubin JH, Brinton LA. Uterine cancer after use of clomiphene citrate to induce ovulation. Am J Epidemiol 2005; 161(7):607-15. PMID: 15781949
89. Brinton L, **WESTHOFF CL**, Scoccia B, et al. Causes of infertility as predictors of subsequent cancer risk. Epidemiology 2005; 16:500-507. PMID: 15951668
90. Brinton LA, Moghissi K, Scoccia B, **WESTHOFF CL**, Lamb EJ. Ovulation induction and cancer risk. Fertil Steril 2005; 83:261-274. PMID: 15705362
91. \* Heller D, Murphy P, **WESTHOFF CL**. Are germinal inclusion cysts markers of ovulation? Gynecol Oncol 2005; 96:496-99. PMID: 15661241
92. \* Murphy P, Kern S, Stanczyk F, **WESTHOFF CL**. Interaction of St. John’s Wort with oral contraceptives: Effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity, and breakthrough bleeding. Contraception 2005; 71(6):402-8. PMID: 15914127
93. Sneed R, **WESTHOFF CL**, Morroni C, Tiezzi L. A prospective study of immediate initiation of depo medroxyprogesterone acetate contraceptive injection. Contraception 2005; 71:99-103. PMID: 15707558
94. Brinton L, Scoccia B, Moghissi K, **WESTHOFF CL**, Althuis M, Mabie J, Lamb E. Breast cancer risk associated with ovulation-stimulating drugs. Hum Reprod 2004; 19(9):2005-13. PMID: 15217997
95. Davis AR, Robilotto C, **WESTHOFF CL**, Forman S, and Zhang J for the NICHD Management of Early Pregnancy Failure Trial Group. Bleeding patterns after vaginal misoprostol for treatment of early pregnancy failure. Hum Reprod 2004:19(7):1655-8. PMID: 15178656
96. \* Morroni C, Grams M, Tiezzi L, **WESTHOFF CL**. Immediate monthly combination contraception to facilitate initiation of the Depo-medroxy progesterone acetate contraceptive injection (DMPA). Contraception 2004; 70:19-23. PMID: 15208048
97. \* Creinin MD, Fox M, Teal S, Chen A, Schaff E, Meyn L, **WESTHOFF CL**. A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for Abortion. Obstet Gynecol 2004; 103(5):851-859. PMID 15121556
98. \* Brinton LA, Lamb EJ, Moghissi KA, Scoccia B, Althuis MD, Mabie JE, **WESTHOFF CL**. Ovarian cancer risk following use of ovulation-stimulating drugs. Obstet Gynecol 2004; 103(6):1194-203. PMID: 15172852
99. \* Brinton LA, Lamb EJ, Moghissi KA, Scoccia B, Althuis MD, Mabie JE, **WESTHOFF CL.** Ovarian cancer risk associated with varying causes of infertility. Fertil Steril 2004 82(2):405-414. PMID: 15302291
100. Creinin MD, Harwood B, Guido R, Fox MC, **WESTHOFF CL**, Zhang J for the NICHD Management of Early Pregnancy Failure Trial. Endometrial thickness after misoprostol use for early pregnancy failure. Int J Gynaecol Obstet 2004; 86:22-26. PMID: 15207665
101. Gilles JM, Creinin MD, Barnhart K, **WESTHOFF CL**, Frederick MM, Zhang J. A randomized trial of saline solution-moistened misoprostol versus dry misoprostol for first trimester pregnancy failure. Am J Obstet Gynecol 2004; 190:389-94. PMID: 14981379
102. Kerns J, **WESTHOFF CL**, Morroni C, Murphy PA. Partner influence on early oral contraceptive discontinuation in a predominantly Hispanic population. Persp Sex Reprod Health 2003; 35(6):256-60. PMID:14744657
103. **WESTHOFF CL**. Emergency Contraception. N Engl J Med 2003; 349:1830-35. PMID: 14602882
104. Guise JM, Palda V, **WESTHOFF CL**, and Lieu TA. The effectiveness of primary care-based interventions to promote breastfeeding: Systematic evidence review and meta-analysis. Ann Fam Med 2003; 1:70-78. PMID: 15040435
105. **WESTHOFF CL**. Depot-medroxyprogesterone acetate injection (Depo-Provera): A highly effective contraceptive option with proven long-term safety. Contraception 2003; 68:75-87. PMID: 12954518
106. **WESTHOFF CL**, Picardo L, Morrow E. Quality of life following early abortion: A comparison of medical and surgical approaches. Contraception 2003; 67:41-47. PMID:12568841
107. **WESTHOFF CL**, Morroni C, Kerns J, Murphy PA. Bleeding patterns after immediate versus conventional oral contraceptive initiation: a randomized controlled trial. Fertil Steril 2003; 79:322-329. PMID:12568841
108. Berg AO, Allen JD, Frame PS, Homer CJ, Johnson MS, Klein JD, Lieu TA, Mulrow CD, Orleans CT, Peipert JF, Pender NJ, Siu AL, Teutsch SM, **WESTHOFF CL**, Woolf SH. Newborn hearing screening: Recommendations and rationale. Am J Nurs 2002; 102(11):83-9. PMID: 12436079
109. \* Schaff EA, Fielding SL, **WESTHOFF CL**. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. Contraception 2002; 66(4):247-50. PMID: 12413620
110. Berg AO, Allen JD, Frame PS, Homer CJ, Lieu TA, Mulrow CD, Orleans CT, Peipert JF, Pender NJ, Sox HC Jr, Teusch SM, **WESTHOFF CL**, Woolf SH. Screening for chlamydia infection: Recommendation and rationale. Am J Nurs 2002; 102(10):87-92. PMID: 12394311
111. **WESTHOFF CL**, Kerns J, Morroni C, Cushman L, Tiezzi L, Murphy PA. Quick start: A novel oral contraceptive initiation method. Contraception 2002; 66:141-145. PMID:12384200
112. \* Davis AR, Nowygrod S, Shabsigh R, **WESTHOFF CL**. The influence of vaginal bleeding on the sexual behavior of urban, Hispanic women and men. Contraception 2002; 65:351-355. PMID: 12057788
113. \* Schaff EA, Fielding SL, **WESTHOFF CL**. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception 2001; 64(2):81-5. PMID: 11704083
114. \* Davis AR, **WESTHOFF CL**. Primary dysmenorrhea in adolescent girls and treatment with oral contraceptives. J. Ped Adol Gyn 2001; 14:3-8. PMID 11358700
115. \* Guise J-M, Mahon SM, Aickin M, Helfand M, Peipert JF, **WESTHOFF CL**. Screening for bacterial vaginosis in pregnancy. Am J Prev Med 2001; 20:62-72. PMID: 11306234
116. Allen R, **WESTHOFF CL**, DeNonno L, Fielding S, and Schaff E. Curettage after mifepristone induced abortion: Frequency, timing and indications. Obstet Gynecol 2001; 98:101-6. PMID: 114306234
117. \* Elul B, Pearlman E, Sorhaindo A, Simonds W, **WESTHOFF CL**. In-depth interviews with medical abortion clients: thoughts on the method and home administration of misoprostol. J Am Med Womens Assoc 2000; 55(3S):169-72. PMID: 10846331
118. **WESTHOFF CL**, Dasmahaptra R, Schaff E. Analgesic during at-home use of misoprostol as part of a medical abortion regimen. Contraception 2000; 62:311-14. PMID:11239618
119. De Nonno LJ, **WESTHOFF CL**, Fielding S, Schaff E. Timing of pain and bleeding after mifepristone-induced abortion. Contraception 2000; 62:305-9. PMID: 11239617
120. Britton J, **WESTHOFF CL**, Gammon M, Wright T. Lactose and benign ovarian tumors in a case-control study. Br J Cancer 2000; 83 (11): 1552-55. PMID: 11076667
121. Schaff E, Fielding S, **WESTHOFF CL**, Ellertson C, Eisinger S, Stadalius L, Fuller L,. Vaginal misoprostol administered 1, 2, or 3 after mifepristone for abortion. A randomized trial. JAMA 2000; 284(15):1948-53. PMID: 11035891
122. **WESTHOFF CL**, Murphy P, Heller D. Predictors of ovarian follicle number. Fertil Steril 2000; 74(4):624-628. PMID: 11020495
123. **WESTHOFF CL**, Dasmahapatra R, Winikoff B, Clarke S. Predictors of analgesic use during supervised medical abortion. Contraception 2000; 61:225-229. PMID: 10827337
124. **WESTHOFF CL**, Britton J, Gammon M, Wright T, Kelsey J. Oral contraceptives and benign ovarian tumors. Am. J Epidemiol 2000; 152; 242-246. PMID: 10933271
125. Britton J, **WESTHOFF CL**, Howe G, Gammon M. Diet and benign ovarian tumors (United States). Cancer Causes and Control 2000; 11:389-401. PMID: 10877332
126. **WESTHOFF CL**, Heller D, Drosinos S, Tancer ML. Risk factors for hyperplasia-associated versus atrophy-associated endometrial carcinoma. Am J Obstet Gynecol 2000; 182:506-508. PMID: 10739499
127. Davis A, **WESTHOFF CL**, De Nonno L. Bleeding patterns after early abortion with mifepristone and misoprostol or manual vacuum aspiration. J Am Wom Med Assn 2000; 55:141-144. PMID: 10846324
128. Kaunitz AM, Garceau RJ, Cromie MA, and the Lunelle Study Group. Comparative safety, efficacy, and cycle control of Lunelle™ monthly contraceptive injection (Medroxyprogesterone acetate and estradiol cypionate ingectable suspension) and Ortho-Novum® 7/7/7 oral contraceptive (Norethindrone/Ethinyl estradiol triphasic). Contraception 1999; 60:179-187. PMID: 10640164
129. **WESTHOFF CL**, Winikoff B, Ellertson C, Elul B, Sivin I for the Mifepristone Clinical Trials Group. Acceptability and feasibility of early pregnancy termination by mifepristone-misoprostol: Results of a large multicenter trial in the U.S. Arch Fam Med 1998; 7:360-66. PMID: 9682690
130. **WESTHOFF CL**. Oral contraceptives and thrombosis: an overview of study methods and recent results. Am J Obstet Gynecol 1998; 179: S38-S42. No PubMed ID
131. **WESTHOFF CL**, Truman C, Kalmuss D et al. Depressive symptoms and Depo-provera. Contraception1998; 57:237-240. PMID: 9649914
132. **WESTHOFF CL**, Truman C, Kalmuss D et al. Depressive symptoms and Norplant Contraceptive Implants. Contraception 1998; 57:241-45. PMID: 9649914
133. Neu N, Grumet S, Saiman L, McMahon D, **WESTHOFF CL**. Genital chlamydial disease in women: Novel risk factors in a low prevalence population. Sex Trans Dis 1998; 25:317-21. PMID: 9662767
134. \* Pirog E, Heller D, **WESTHOFF CL**. Endometrial adenocarcinoma - Lack of correlation between treatment delay and tumor stage. Gynecol Oncol. 1997; 67:303-308. PMID: 9441779
135. Zacur H, Kaufman S, Smith B, **WESTHOFF CL**, Helbig D, Lee Y, Gentile G. Does creatinine adjustment of urinary pregnanediol glucuronide reduce or introduce measurement error? Gynecol Endocrinol 1997; 11:29-33. PMID: 9086337
136. Heller D, **WESTHOFF CL**, Gordon R. The relationship between perineal cosmetic talc usage and ovarian talc particle burden. Am J Obstet Gynecol 1996; 174:1507-10. PMID: 9065120
137. **WESTHOFF CL**. Current assessment of the use of intrauterine devices. J. Nurse-Midwifery 1996; 41:218-23. PMID: 8708805
138. Heller D, Gordon R, **WESTHOFF CL**, Gerber S. Asbestos exposure and ovarian asbestos fiber burden. Am J Ind Med 1996; 29:435-39. PMID: 8732916
139. **WESTHOFF CL**, Gentile G, Lee J, Zacur H, Helbig D. Predictors of ovarian steroid secretion in reproductive age women. Am J Epidemeol 1996; 144:381-89. PMID: 8712195
140. **WESTHOFF CL**, Wieland D, Tiezzi L. Depression in users of Depo medroxyprogesterone acetate. Contraception 1995; 51:351-354. PMID: 7554975
141. Bass K, **WESTHOFF CL**, Bush T. Ovarian cancer: Epidemiologic and clinical perspectives and the feasibility of screening. Menopause 1995; (2):145-158. No PubMed ID
142. Gerber S, **WESTHOFF CL**, Lopez M, Gordon L. Norplant use in a New York City clinic population. Contraception 1994; 49:557-564. PMID: 8070260
143. Gollub E, **WESTHOFF CL**, Timor-Tritsch I. Detection of ovaries by transvaginal sonography in postmenopausal women. Ult Obstet Gyn 1993; 3:422-425. PMID: 12797244
144. **WESTHOFF CL**, Marks F, Rosenfield A. Residency training in contraception, sterilization, and abortion. Obstet Gynecol 1993; 81:311-314. PMID: 8423971
145. **WESTHOFF CL**, Murphy P, Heller D, Halim A. Is ovarian cancer associated with an increased frequency of germinal inclusion cysts? Am J Epidemeol 1993; 138:90-93. PMID: 8342533
146. **WESTHOFF CL,** Levin B, Ladd G, O’Conner J. Sources of variability in normal CA 125 levels. Cancer Epidemiol Biomarkers Prev 1992; 1(5):357-9. PMID: 1305467
147. **WESTHOFF CL**, Clark C. Benign ovarian cysts in the United States and England & Wales. BJOG 1992; 99:329-32. PMID: 1581280
148. Kelly A, Marks F, **WESTHOFF CL**, Rosen M. The effect of the New York State restrictions on resident work hours. Obstet Gynecol 1991; 78: 468-73. PMID: 1876386
149. **WESTHOFF CL**, Randall MC. Ovarian cancer screening - potential effect on mortality. Am J Obstet Gynecol 1991; 165:502-5. PMID: 1892173
150. Sassone AM, Timor-Tritsch IE, Artner A, **WESTHOFF CL**, Warren WB. Transvaginal sonographic characterization of ovarian pathology: Evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol 1991 78:70-76. PMID: 2047071
151. \* Rosen MG, Dickinson JC, **WESTHOFF CL**. Vaginal birth after cesarean: a meta-analysis of morbidity and mortality. Obstet Gynecol 1991; 77:465-70. PMID: 1825136
152. **WESTHOFF CL**, Gollub E, Patel J, Rivera H, Bast R. CA-125 Levels in Menopausal Women. Obstet Gynecol 1990; 76:428. PMID: 2381621
153. **WESTHOFF CL**, Pike M, Vessey M. Benign Ovarian Teratomas: A population-based case-control study. Br J Cancer 1988; 58:93-98. PMID: 3166898
154. Vessey M, Metcalfe A, Wells C, McPherson K, **WESTHOFF CL**, Yeates D. Ovarian neoplasms, functional ovarian cysts and oral contraceptives. BMJ 1987; 294:1518. PMID: 3111618
155. Howe G, **WESTHOFF CL**, Vessey M, Yeates D. Effects of age, cigarette smoking and other factors on fertility; findings in a large prospective study Effects of age, cigarette smoking and other factors on fertility; findings in a large prospective study her factors on fertility; findings in a large prospective study. BMJ 1985; (290)1697-700. PMID: 3924219
156. **WESTHOFF CL**, Beral V. Patterns of ovarian cyst hospital discharge rates in England and Wales, 1962-1979. BMJ 1984; 289:1348-9. PMID: 6437545

*B.* ***Reviews, Chapters, Monographs and Editorials***

1. **Westhoff CL**. Contraception and Contraception: X – our new “mirror” journal. Contraception 2019; 99(6): 321-322. PMID 31160000
2. **Westhoff CL,** Davis, AR. Abortion-related adverse events by facility type: Reassurance from a national analysis. JAMA 2018; 319(24):2481-2483. PMID 29946708
3. **Westhoff CL**, Pike MC. Hormonal contraception and breast cancer. Am J Obstet Gynecol 2018 Aug; 219(2):169.e1-169.e4. PMID 30193687
4. **Westhoff CL**. A better medical regimen for the management of miscarriage. N Engl J Med, June 7 2018(378):2232-2233. PMID 29874544
5. Lopez LM, Bernholc A, Chen M, Grey TW, Otterness C, **Westhoff C**, Edelman A, Helmerhorst FM. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev. 2016 Aug 18; PMID: 27537097
6. Ohly NT**, WESTHOFF CL**. “Intrauterine Contraception: Comparison of the Copper T Intrauterine Device with the Levonorgestrel Intrauterine Systems”. In *The Handbook of Contraception: A Guide for Practical Management, 2nd Edition*. Eds. Shoupe D, Mishell D. Switzerland: Humana Press, 2015:165-180. No PubMed ID
7. **WESTHOFF CL**. December 2015. Contraception 2015; 92(6):513. PMID: 26585715
8. \* Darney P, Creinin MD, Nichols M, Gilliam M, **WESTHOFF CL.** Tenth anniversary of the Society of Family Planning. Contraception 2015; 92(4):279-81. PMID: 26272310
9. Winikoff B, **WESTHOFF CL.** Fifteen years: Looking back, looking forward. Contraception 2015; 92(3):177-8. PMID: 26142617
10. **WESTHOFF CL.** Developing highly effective, long-acting, and reversible contraception. Blog post for the Population Council. Published online Sept 2015. No PubMed ID
11. **WESTHOFF CL** Winikoff B. DMPA and HIV: Do we need a trial? Contraception 2014; 90(4):353. PMID: 25183262
12. **WESTHOFF CL**. Journal update: What’s new for 2014. Contraception 2014; 89(1):1-2. PMID: 24290984

1. Rivlin K, **WESTHOFF CL**. Hormonal contraception and obesity: A multi-faceted concern. Gynaecology Forum. 2014; 19(2):13-16. No PubMed ID
2. Castano PM, **WESTHOFF CL**. How to measure contraceptive adherence: An ongoing research challenge. Contraception 2013; 88(4):475-6. PMID: 24034805
3. **WESTHOFF CL.** Contraception and the advances in Family Planning. Contraception 2013; 87(1):1-2. PMID: 23228851
4. **WESTHOFF CL**, among many. A statement on abortion by 100 professors of obstetrics: 40 years later. Contraception 2013; 88(4):568-76. Am J Obstet Gynecol. 2013 Sep;209(3):193-9 PMID: 23500455, PMID: 24034806
5. **WESTHOFF CL**, Finer L, Teal S. Featured research at the 2013 North American Forum on Family Planning. Contraception 2013; 88(3):319-20. PMID: 23896346
6. Shields WC, Dominguez L, **WESTHOFF CL**. ARHP’s 50th anniversary: Five decades of provider education in sexual reproductive health. Contraception 2013; 88(2):197-9. PMID: 23845209
7. **WESTHOFF CL**, Bowen T. New guidelines for authors. Contraception 2013; 88(1):1-2. PMID: 23773526
8. **WESTHOFF CL**, Finer L, Teal S. Featured research at the 2012 North American Forum on Family Planning. Contraception 2012; 86(3):187. PMID: 22770788
9. Cleland K, Peipert JF, **WESTHOFF CL**, Spear S, Trussell J. Plan B, one step not taken: Politics trumps science yet again. Contraception 2012; 85(4):340-1. PMID: 22305916
10. Cleland K, Peipert JF, **WESTHOFF CL**, Spear S, Trussell J. Family Planning as a cost-saving preventive health service. N Engl J Med 2011; 364(18):e37. PMID: 21506736
11. Maguire K, **WESTHOFF CL**. The state of hormonal contraception today: established and emerging non-contraceptive health benefits. Am J Obstet Gynecol 2011; 205(4 Suppl):S4-8. PMID:21961824
12. **WESTHOFF CL**. Second-trimester abortion for fetal anomalies or fetal death: A comparison of techniques. Obstet Gynecol 2011; 117(4):775-6. PMID: 21422846
13. Reid RL, **WESTHOFF CL**, Mansour D, de Vries C, Verhaeghe J. Oral contraceptives and venous thromboembolism consensus opinion from an international workshop held in Berlin, Germany in December 2009. J Fam Plann Reprod Health Care 2010; 36(3):117-22. PMID: 20659363
14. Beasley A, Cepin A, **WESTHOFF CL**. “Pregnancy Termination”. *Precis. Gynecology, 4th Edition*. Washington D.C: The American College of Obstetricians and Gynecologists, 2010. No PubMed ID
15. Benrubi G, Edelman A, Grimes D, Kaunitz A, MacIsaac L, **WESTHOFF CL**. APGO Contraception Module. Including: monograph, case studies, PowerPoint slides, and audio podcasts 2009. No PubMed ID
16. Goldberg A, Carusi D, **WESTHOFF CL.** “Pregnancy Loss”. In *Management of Unintended and Abnormal Pregnancy*. Eds. Paul M, Lichtenberg E, Borgatta L, Grimes D, Stubblefield P, Creinin M. Sussex, England: Blackwell Publishing, 2009: 264-279. No PubMed ID.
17. Feisullin K, **WESTHOFF CL**. “Contraception”. In *Principles of Gender-Specific Medicine*, *2nd Edition*. Ed. Legato MJ. London: Academic Press, 2009: 357-365. No PubMed ID
18. O'Connell K, **WESTHOFF CL**. Pharmacology of hormonal contraceptives and acne. Cutis 2008; (81):8-12. PMID: 18338652
19. **WESTHOFF CL**. The sterilization movement and global fertility in the twentieth century: A review. N Engl J Med 2008; 359(17):1854-55. No PubMed ID
20. Kaunitz AM, **WESTHOFF CL**. Combination hormonal contraception & venous thromboemolism risk. OBG management 2008; S1-S11 (suppl). No PubMed ID
21. Shimoni N, **WESTHOFF CL**. Review of the vaginal contraceptive ring (NuvaRing). J Fam Plann Reprod Health Care 2008 ; 34(4):247-50. PMID: 18854070
22. O’Connell K, **WESTHOFF CL**. Success rate and duration of bleeding after medical abortion were not improved by 7 additional days of oral misoprostol [commentary]. EBOG 2008 6:116-7. No PubMed ID
23. Smith D, **WESTHOFF CL**. Sociocultural and multicultural issues in contraception counseling. Dialogues Contracept 2007; 11(4):1-5. No PubMed ID
24. **WESTHOFF CL**. “Risk of Pulmonary Embolism/Venous Thrombosis”. *In Treatment of the Post-Menopausal Woman*. Ed. Lobo R. Cambridge MA: Academic Press, 2000: 607-615. Also in 3rd Edition, published 2007: 491- 506. No PubMed ID
25. Estes C, **WESTHOFF CL**. Contraception for the transplant patient. Semin Perinatol 2007 Dec; 31(6):372-7. PMID: 18063121
26. **WESTHOFF CL**. IUDs and colonization or infection with actinomyces. Contraception 2007; 75: S48-S50 (suppl). PMID: 17531616
27. **WESTHOFF CL**. O’Connell K. Menstrual bleeding: Is it necessary and how can heavy bleeding be managed? The Female Patient 2007; pp 4-6. No PubMed ID
28. Darney P, **WESTHOFF CL**. Advances in sterilization. Dialogues Contracept 2007 fall: 2(3). No PubMed ID
29. \* Schafer J, Osborne L, Davis A, **WESTHOFF CL**. Acceptability and satisfaction using QuickStart with the contraceptive vaginal ring versus an oral contraceptive. Contraception 2006; (7)3:488-92. PMID: 1662703
30. **WESTHOFF CL**. Non-contraceptive benefits of long-term reversible contraception. MPR OB/GYN edition. 2006; pp 13-14. No PubMed ID
31. Shulman LP, **WESTHOFF CL**. Contraception and cancer. Dialogues Contracept 2006; 10(3):5-7. No PubMed ID
32. Burkman RT, Grimes DA, Mishell DR, **WESTHOFF CL**. Benefits of contraception to women’s health: An evidence- based perspective. Dialogues Contracept 2006; 10(3):1-4. No PubMed ID
33. Shulman LP, **WESTHOFF CL**. Return to fertility after use of reversible contraception. Dialogues Contracept 2006; 10(1):1-3. No PubMed ID
34. **WESTHOFF CL**. Sterilization regret and long-acting methods of reversible contraception. The Forum 2006; 4:6-10. No PubMed ID
35. Swica Y, **WESTHOFF CL**. Update on new contraceptive choices. JCOM 2006; 13:447-54. No PubMed ID
36. **WESTHOFF CL**. “Emergency Contraception”. In *Clinical Practice: The New England Journal of Medicine.* Eds. Solomon C and Drazen J. New York: McGraw-Hill, 2006: 131-139. No PubMed ID
37. **WESTHOFF CL**. Tubal sterilization: A review of the advantages and disadvantages. The Female Patient 2006:17-20(suppl). No PubMed ID
38. **WESTHOFF CL**. “Contraceptive adherence and continuation rates”. In *RCOG 49th study group*. Ed. Glasier A. London: RCOG, 2005.
39. **WESTHOFF CL.** Contraceptive choices for HIV-infected and at-risk women: Review of available contraceptives. JAIDS 2005; 38:S3(suppl). PMID: 15867612
40. **WESTHOFF CL**, Mishell, D. New breast cancer findings: No increased risk in women with and without mutations with oral contraceptive use. Dialogues Contracept 2005; 9(3):9-10. No PubMed ID
41. Andolsek KM, **WESTHOFF CL**. Contraception and weight changes. Dialogues Contracept 2005; 9(3):8. No PubMed ID
42. **WESTHOFF CL**. Initiating and maintaining contraception. The Forum 2005; 3:11-14. No PubMed ID
43. Kaunitz A, Perlmutter J, **WESTHOFF CL**. Preconception care and contraception. Dialogues Contracept 2005; 8:1-4. No PubMed ID
44. **WESTHOFF CL**, Wysocki S. Medical eligibility for contraceptive use. The Forum 2004; 2:12-13. No PubMed ID
45. **WESTHOFF CL**. Depot-medroxyprogesterone acetate injection (Depo-Provera®): A highly effective contraceptive option with proven long-term safety. Contraception 2003; 68(2):75-87. PMID: 12954518
46. Speroff L, **WESTHOFF CL**. Smoking and oral contraception. Dialogues Contracept 2003; 8:4-5. No PubMed ID
47. **WESTHOFF CL**, Schnare SM. Male and female sterilization: An update. Dialogues Contracept 2003; 8:5-7. No PubMed ID
48. **WESTHOFF CL**. Understanding contraceptive effectiveness. Dialogues Contracept 2002; 7:1-8. No PubMed ID
49. **WESTHOFF CL**. Bone mineral density and DMPA. J Reprod. Med 2002; 47(9 suppl):795-9. PMID: 12380409
50. Kaunitz AM, **WESTHOFF CL**, Leonhardt KK. Therapeutic options to reduce or halt menstruation. The Female Patient 2002:12-16(suppl). No PubMed ID
51. Kaunitz AM, **WESTHOFF CL**, Coddington III CC, Anderson FD, Simon JA. Regulating menstruation: Impact of lifestyle and medical conditions. The Female Patient 2002:8-11(suppl). No PubMed ID
52. **WESTHOFF CL**, Kaunitz AM. An overview of menstruation. The Female Patient 2002:4-7(suppl). No PubMed ID
53. Kaunitz AM , **WESTHOFF CL**. Continuous oral contraceptive use. The Female Patient 2002:3-4(suppl). No PubMed ID
54. **WESTHOFF CL**. Criteria for appropriate birth control. Gynecol Endocrinol. 2001; 15(Suppl 3):19-22. PMID: 11570314
55. **WESTHOFF CL**. Oral contraceptives: Making evidence-based clinical decisions. Int J Fert 2001. No PubMed ID
56. **WESTHOFF CL**, Grimes DA, Creinin MD. Pharmacologic evacuation of the pregnant uterus. Discussion. ACOG Continuing Education. 2001; (27):1-9. No PubMed ID
57. **WESTHOFF CL**. Pivotal epidemiological studies. Dialogues Contracept 2001; (7):5. No PubMed ID
58. **WESTHOFF CL**. Tubal Sterilization - Safe and effective. N Engl J Med 2000; 343(23):1724. PMID: 11106724
59. **WESTHOFF CL**, Kushner R, Mishell DR. Hormonal contraception and weight issues. Dialogues Contracept 2000; (6):5. No PubMed ID
60. **WESTHOFF CL**. Intrauterine devices. In CREOG Contraception Curriculum 2000 (CD-ROM).

1. **WESTHOFF CL**. Evidence-based medicine: An overview. Int J Fert 2000; 45:57-63 (suppl). No PubMed ID
2. **WESTHOFF CL**, Davis A. Tubal sterilization: Focus on the United States experience. Fertil Steril 2000; 73:913-22. PMID:10785216
3. **WESTHOFF CL**. “Risk of Pulmonary Embolism/Venous Thrombosis”. In *Menopause: Biology and Pathobiology*. Eds. Lobo R, Marcus R, Kelsey J. Cambridge MA: Academic Press, 2000: 607-615. No PubMed ID
4. **WESTHOFF CL**. Oral contraceptives and cardiovascular risk: An end to the debate? Contraception 2000; 62:1S-2S (suppl). PMID: 11102596
5. **WESTHOFF CL**. Thoughtful screening. Am Wom Med Assn 2000; 55:206. PMID: 10935352
6. **WESTHOFF CL**. “Contraception and Abortion”. In *Women’s Primary Care, 2nd edition*. Eds. Seltzer V, Pearse W. New York: McGraw-Hill. 1999: 207-226. No PubMed ID
7. Zimmerman R, **WESTHOFF CL**. “Gynecologic Cancers”. In *Multiple Primary Cancers*. Eds. Neugut A, Robinson E, Meadows A. Philadelphia: Lippincott Williams & Wilkins. 1999. No PubMed ID
8. Ellertson C, **WESTHOFF CL**. “Procedure Selection”. In *A Clinician’s Guide to Medical and Surgical Abortion*. Eds. Paul M, Grimes D, Litchenberg E, Borgatta L, Stubblefield P. San Diego CA: Harcourt, Brace & Co. 1999: 63-69. No PubMed ID
9. **WESTHOFF CL**. Breast cancer risk: Perception versus reality. Contraception 1999; 59(1S):25S-28S (suppl). PMID:10342093
10. **WESTHOFF CL**. False hope: Mammography before age 50 promotes unnecessary anxiety. The Female Patient (Primary Care Edition) 1999; 24:22-35. The Female Patient (Ob/Gyn edition) 1998; 23:32-44. No PubMed ID
11. **WESTHOFF CL**. Contraception at age 35 years and older. Clin Obstet Gynecol 1998; 41:951-57. PMID: 9917950
12. **WESTHOFF CL.** IFFS newsletter, Autumn 1998. No PubMed ID
13. **WESTHOFF CL**. Non-contraceptive health benefits of OCs. Dialogues Contracept 1997; 197:29-36. No PubMed ID
14. **WESTHOFF CL**. Abortion and breast cancer: Good news at last. IPPF Medical Bulletin 1997; 31(2):1-2. No PubMed ID
15. Speroff L, **WESTHOFF CL**. Breast disease and hormonal contraception: Resolution of a lasting controversy. Dialogues Contracept 1997; 5(3). No PubMed ID
16. **WESTHOFF CL**. National Institutes of Health Consensus Development Panel. NIH consensus statement: Breast cancer screening for women 40-49. J National Cancer Inst 1997; 89:1015-26. No PubMed ID
17. **WESTHOFF CL**. Pre-insertion patient counseling and follow-up. Dialogues Contracept 1996:44-51. No PubMed ID
18. \* Darney P, Kaunitz A, Mishell D, Speroff L, Sulak P, **WESTHOFF CL**. Current clinical issues in oral contraception. Contemporary Ob/Gyn 1996 41; S3-S38(suppl). No PubMed ID
19. **WESTHOFF CL**. The IUD in evolution. Ob Gyn Survey 1996 51:S20-S24(suppl). PMID: 8972498

1. **WESTHOFF CL**. A perspective on the concept of “risk”. Dialogues Contracept 1996; 5(1). PMID: 12347723
2. **WESTHOFF CL**. Oral contraceptives and venous thromboembolism: Should epidemiologic associations drive clinical decision making? Contraception 1996; 54:1-3. PMID: 8804800
3. **WESTHOFF CL**. Ovarian cancer. Ann Rev Pub Hlth 1996; 17:85-96. PMID: 8724217
4. **WESTHOFF CL**. Oral contraceptives and breast cancer - Resolution emerges. Contraception 1996, 54:1-2 (suppl). No PubMed ID.
5. **WESTHOFF CL**. Depot medroxyprogesterone acetate contraception: Metabolic parameters and mood changes. J Reprod Med 1996; 41:401-06. PMID: 8725702
6. **WESTHOFF CL**. Ovarian Cancer. Ann Rev of Pub Hlth 1996; 17:85-96. PMID: 8724217
7. **WESTHOFF CL**. Infertility and breast cancer risk. Gyn Oncol 1996; 60:1-2. PMID: 8557219
8. **WESTHOFF CL**. Epidemiologic studies: Pitfalls in interpretation. Dialogues Contracept 1994; 4(5):5-8. No PubMed ID
9. **WESTHOFF CL**, Marks F, Rosenfield A, Roig A, Nicholas A. “Clinical and Legal Factors Influencing IUD Use in the U.S." In *A New Look at IUD's - Advancing Contraceptive Choices*. Eds. Bardin C, Mishell D. Oxford: Butterworth-Heinemann, 1994:100-8. No PubMed ID.
10. **WESTHOFF C**L. Abortion training in residency programs. JAMWA 1994 49:150-2. No PubMed ID
11. **WESTHOFF C**. Current status of screening for ovarian cancer. Gyn Onc 1994 55:S34-S37.
12. **WESTHOFF CL**. Oral contraception benefits beyond pregnancy prevention in the fourth decade of oral contraception. Dialogues Contracept 1993. No PubMed ID
13. **WESTHOFF CL**, Rosenfield A. The impact of family planning on women's health. Curr Op Obstet Gynecol 1993; 5:793-7. PMID: 8286692
14. **WESTHOFF CL**: "Epidemiology of Infertility". In *Reproductive and Perinatal Epidemiology*. Ed. Kiely M. Boca Raton, FL: CRC Press, 1990: 43-61. No PubMed ID.
15. Siegler AC, Wang C, and **WESTHOFF CL**. Management of unruptured tubal pregnancy. Obstet Gynec Survey 1981; 36:599. No PubMed ID

*C.* ***Case Reports***

None

## *D. Letters to the Editor*

1. Fu A, Weber CE, Davis AR, Gilmore E, Hirsch G, **Westhoff CL**. Response re: A non-inferiority randomized controlled trial to compare transabdominal and transvaginal sonography for eligibility assessment prior to medical abortion. Contraception. 2019 Jun; 99(6):378. PMID 30935959
2. Kaunitz A, Portman D, **WESTHOFF CL,** Archer DF, Mishell DR Jr, Foegh

M**.** In Reply. Obstet Gynecol. 2014; 123(5):1108. PMID: 24785870

1. Keyes KM, Cheslack-Postava K, **Westhoff C**, Heim CM, Haloossim M, Walsh K, Koenen K. Keyes at Al. responde to “hormonal contraception and mood.” Invited commentary. Am J Epidemiol. 2013 Nov 1; 178(9):1392-3. PMID 24043438
2. **WESTHOFF CL**, Pike M. Pharmacokinetics of a combined oral contraceptive in obese and three normal-weight women. Contraception 2010; 82(6):581-2. No PubMed ID
3. Fjerstad M, **WESTHOFF CL**, Lifford KL. Immediate complications after medical compared with surgical termination of pregnancy. Obstet Gynecol 2010; 115(3): 660-1. PMID: 2017730
4. Rickert VI, Tiezzi L, Lipshutz J, Leon J, Vaughan R, **Westhoff C**. Elusive denominators and the illusions they create. J Adol Health 2007; 41: 315-16 PMID 17707304

1. **WESTHOFF CL**. Factor V Leiden and third-generation oral contraceptives. The Lancet 1996; 347:396. PMID: 8598719
2. Heller D, Berk H, Drosinos S, **WESTHOFF CL**, Tancer ML. Does endometrial biopsy miss endometrial carcinoma? IJOG 1995; 48(1):107-8. PMID: 7698370
3. **WESTHOFF CL**. Current status of ovarian cancer screening. Gynecol Oncol 1994; 55:S34-S37(suppl). PMID 7835807
4. Heller D, Drosinos S, **WESTHOFF CL**: Accuracy of tumor grade assigned at initial endometrial sampling. Int J Gynaecol Obstet 1994 Dec; 47(3):301-2. PMID: 7705543
5. **WESTHOFF CL**. Past IUD use and risk of tubal pregnancy. Epidemiology. 1994 Jan; 5:129-30. PMID: 8117774
6. **WESTHOFF CL**. Profiles of women age 30-39 and age less than 30 with epithelial ovarian cancer. Obstet Gynecol 1993; 82(4):637-8. PMID: 8377995

## E. *Other Publications (Including Published Abstracts)*

1. Creinin MD, **Westhoff CL**. Six-year contraceptive efficacy and continued safety of a levonorgestrel 52mg intrauterine system. Anticipated presentation at American College of Obstetrics and Gynecology Annual Meeting, Seattle, WA, April 24, 2020. Published in Contraception (in press).
2. **Westhoff CL**. Efficacy of LF111 in obese women, an investigational progestin-only oral contraceptive. Presentation at 75th Scientific Congress & Expo of the American Society for Reproductive Medicine, Philadelphia, PA, October 16, 2019.
3. Kohn J, Simon H, **Westhoff CL**. Measuring Quality of Contraceptive Care: Assessing the Provision of Contraception at Planned Parenthood Health Centers. Presentation at: 2017 Annual Research Meeting, New Orleans, LA, 6/2017.
4. Chernick L, Wu M, Castano C, Schnall R, **WESTHOFF CL,** Santelli J, Dayan, P. The texting 2 initiate study: A randomized controlled trial using text messaging to increase contraception initiation among adolescent females in the emergency department. Presented at: SFP Annual Meeting, Chicago, IL, 11/2015 and The PAS Annual Meeting, Baltimore, MD, 5/16.
5. Teal SB, **WESTHOFF CL**, Keder LM, Darney PD, Blumenthal PD, Creinin MD. Bleeding patterns in women using LilettaTM, a new 52 mg levonorgestrel-releasing intrauterine system, for up to 2 years. Presented at: The Annual Meeting of the Society of Family Planning, Chicago, IL, 11/2015. Published in: Contraception 2015; 92:361-2.
6. Creinin M, **WESTHOFF CL**, Keder L, Darney P, Blumenthal P, Perriera L. Amenorrhea rates in women using the LevosertTM 52 mg levonorgestrel intrauterine system for up to 4 years. Presented at: European Society of Gynecology 2015 Congress, 10/2015, Prague, Czech Republic. Published in: Int J Gynaecol Obstet 2015; (Suppl): E131.
7. Creinin M, Teal S, **WESTHOFF CL**, Keder L, Darney P, Blumenthal P. Bleeding patterns in women using the LevosertTM 52 mg levonorgestrel-releasing intrauterine system for up to 2 years. Presented at: European Society of Gynecology 2015 Congress, Prague, Czech Republic, 10/2015.

1. Creinin M, Teal S, Turok D, Eisenberg D, **WESTHOFF CL**, Keder L. Evaluation of pelvic infection in women using the LevosertTM 52 mg levonorgestrel-releasing intrauterine system for up to 2 years. Presented at: European Society of Gynecology 2015 Congress, Prague, Czech Republic, 10/15.
2. Turok DK, Eisenberg DL, Teal SB, **WESTHOFF CL**, Keder LM, Creinin MD. Evaluation of pelvic infection in women using LilettaTM, a new 52 mg levonorgestrel-releasing intrauterine system, for up to 2 years. International Federation of Gynecology and Obstetrics (FIGO) 2015 Congress, 10/2015, Vancouver, BC, Canada. Published in: Int J Gynecol Obstet 2015; 131(Suppl):E136.
3. **WESTHOFF CL**, Keder LM, Darney PD, Blumenthal PD, Perriera LK, Creinin MD. Amenorrhea rates in women using LilettaTM, a new 52 mg levonorgestrel intrauterine system, for up to 4 years. International Federation of Gynecology and Obstetrics (FIGO) 2015 Congress, 10/2015, Vancouver, BC, Canada, oral presentation. Published in: Int J Gynecol Obstet 2015; 131(Suppl):E136.
4. Brinton L, Niwa S, Ruggier D, Lamb E, Moghissi K, Socia B, **WESTHOFF CL.** Effects of ovulation-stimulating drugs on cancers other than breast and gynecologic malignancies. Presented at: Society for Epidemiologic Research Annual Meeting, Denver, CO, 6/2015.
5. Creinin MD, Baker JB, Eisenberg DL, Ginde S, Turok DK, **WESTHOFF CL.** Levonorgestrel levels in nonobese and obese women using LNG20, a new intrauterine contraceptive. Presented at: ACOG 2015 Annual Clinical Meeting, San Francisco, CA, 5/2015. Published in: Obstet Gynecol 2015; 125 (Suppl):84S-85S.
6. Gibbs S, Darney P, Harper C, Henderson JT, **WESTHOFF CL**, Rocca C. Attitudes of young women in reproductive health clinics toward pelvic examinations by race/ethnicity. Presented at: ACOG Clinical and Scientific Meeting, San Francisco, CA, 4/2015.
7. \* Castano P, Vander Haar E, Brown K, Alyafi M, Velasco M, Kaplan A**, WESTHOFF CL.** Yes we can: Quickstart Initiation of Levonogestrel-releasing intrauterine system (LNG-IUS). Contraception 2014; 90(3):331.
8. Chernick L, Schnall R, Stockwell M, Castano P, Higgins T, **WESTHOFF CL**, Santelli J, Dayan P. Adolescent females’ preferences for a pregnancy prevention intervention using text messaging. Contraception 2014; 90(3):349
9. Nippita S, Velasco MG, Oviedo JD, **WESTHOFF CL**, Davis AR, Castaño PM. 90-day bleeding patterns after intrauterine device insertion: a prospective parallel cohort study. Obstet Gynecol 2014; 123:1:12S (suppl).
10. Nippita S, Velasco MG, Oviedo JD, **WESTHOFF CL**, Davis AR, Castaño PM. Text messages compared with monthly paper diaries: collecting bleeding data after intrauterine device insertion. Obstet Gynecol 2014; 123:1:12S-3S (suppl).
11. Heinemann K, **WESTHOFF CL**, Grimes DA, Moehner S. Intrauterine Devices and the Risk of Uterine Perforations: Final Results from the EURAS-IUD Study. Obstet Gynecol 2014; 123:1:12S-3S (suppl).
12. Tang R, **WESTHOFF CL.** Pharmacokinetic evaluation of ethinyl estradiol in a combined oral contraceptive. Presented at: Measuring Estrogen Exposure and Metabolism, Bethesda, MD, 3/14.
13. Chernick L, **WESTHOFF CL**, Santelli J, Castano P, Schnall R, Stockwell M. Barriers and enablers affecting hormonal contraception non-use among adolescent females presenting to the emergency department. Presented at: Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting in Vancouver, BC, Canada, 2014.
14. Singh MP, Maitra A, Bishop WL, Smith K, Benson J, **WESTHOFF CL**. Building EHR-derived quality measures for clinical quality improvement and population health measurement. Presented at: American Public Health Association Annual conference, New Orleans, LA, 2014.
15. Tang R, Cremers S, Pike MC, Stanczyk FZ, **WESTHOFF CL**. Comparison of an RIA and an LC-MS/MS Method for Measuring Ethinyl Estradiol in Human Serum . Presented at: Endocrine Society Meeting, Measuring Estrogen Exposure and Metabolism, Bethesda, MD, 3/2014.
16. Westhoff C among many. Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism. J Fam Plann Reprod Health Care. 2013 Jul; 39(3):156-9. PMID 23585363 and Eur J Contracept Reprod Health Care 2013 Jun; 18(3):143-7. PMID 23578274
17. Chernick L, Dayan P, Ray M, Garcia M, Garth J, **WESTHOFF CL**, Referring sexually active female adolescents from the emergency department to family planning clinic: Is a wallet card effective? Contraception 2013; 88(2): 308.
18. Hurley C, Sheeder J, **WESTHOFF C**, Teal S. Contraception after second-trimester abortion: characteristics of immediate LARC acceptors and comparative repeat pregnancy rates. Contraception 2012; 86(3):296.
19. Dragoman M, Petrie K, Torgal A, Cremers S, **WESTHOFF C**. Pharmacokinetics of ethinyl estradiol and etonogestrel during extended use of a contraceptive vaginal ring. Contraception 2012; 86(3):291-2.
20. Petrie K, **WESTHOFF C**, Cremers S. Using changes in binding globulins to assess oral contraceptive pill compliance. Contraception 2012; 86(3):312.
21. Langston A, Joslin-Roher S, Azinge S, Rosario Tejeda L, **WESTHOFF C**. Immediate post-abortion access to contraception and repeat pregnancy at 12 months — a cohort study. Contraception 2012; 86(3):298.
22. Beasley A, White K, **WESTHOFF C**. Self versus clinic administration of depot medroxyprogesterone acetate (DMPA): A randomized clinical trial. Contraception 2012; 86(3):315.
23. Siddiqui A, **WESTHOFF C**. Barriers to accessing voluntary postpartum female tubal sterilization among minority and low-income women. Presented at: NAPCRG, Seattle, WA, 11/10. Published in: Contraception 2012 86(2):184.
24. Hall K, Castaño P, **WESTHOFF C**. Menstrual distress symptoms, oral contraceptive-attributed side effects and discontinuation among urban, multi-ethnic adolescent and young adult women: Is there a link? J Adolesc Health 2012; 50(2 Suppl.):S20-S21.
25. Guiahi M, Lim S, Westover C, **WESTHOFF CL**. Enablers and barriers to abortion training in New York City. Contraception 2012; 85(3):321-322.
26. Maguire K, Davis A, Rosario Tejeda L, **WESTHOFF CL**. Intracervical 2% lidocaine gel as an analgesic during intrauterine device insertion: a randomized controlled trial. Contraception 2012; 85(3):324.
27. Mercier R, **WESTHOFF CL**, Castaño PC. Acceptability and use of postabortion resources by urban women — A pilot study. Contraception 2012; 85(3):325.
28. Zimring JC, Welniak L, Semple JW, Ness PM, Slichter SJ, Spitainik SL, NHLBI Alloimmunization Working Group (**Westhoff CL**.) Current problems and future directions of transfusion-induced alloimmunization: summary of an NHLBI working group. Transfusion 2011 Feb; 51(2):435-41. PMID 21251006
29. Langston AM, Rosario LY, **WESTHOFF CL**. Partnership characteristics as predictors for choosing a very effective contraceptive method. Contraception 2010; 82(2): 204.
30. Davis A, **WESTHOFF CL**, Stanzyck F. Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation and bleeding. Contraception 2010; 82(2):194.
31. Stidham Hall K, O’Connell White K, Rickert V, Reame N, **WESTHOFF CL**. Do depressed mood, psychological stress and eating disordered symptoms increase the risk for oral contraceptive discontinuation in young minority women? Contraception 2010; 82(2):186.
32. O’Connell White K, Roca C, **WESTHOFF C**. The impact of pack supply on oral contraceptive continuation: A randomized controlled trial. Contraception 2010; 82(2):185.
33. Shimoni N, **WESTHOFF C**. A randomized trial of immediate versus delayed insertion of the CuT380A following medication abortion. Contraception 2010; 82(2):189.
34. Castaño PM, Mayeda ER, Andrés Martínez R, Lara M, **WESTHOFF C**. Txt Now 2 Decrease Pregnancies L8r: A randomized controlled trial to evaluate the effect of daily educational text messages on oral contraceptive continuation in young urban women. Contraception 2010; 82(2):189.
35. Castaño PM, Polen L, Jackson E, Namerow P, **WESTHOFF CL**. Women’s attitudes and behaviors toward unplanned pregnancy: A prospective study. Contraception 2010; 82(2):205.
36. Torgal AH, Mayeda ER, Dragoman MV, Linker D, **WESTHOFF CL**. Ovarian follicular development during six week extended use of a single contraceptive vaginal ring. Contraception 2010; 82(2):199.
37. Torgal AH, Mayeda ER, Dragoman MV, Linker D, **WESTHOFF CL**. Ovarian suppression in normal-weight and obese women using a contraceptive vaginal ring. Contraception 2010; 82(2):199.
38. Langston A, Rosario L, **WESTHOFF C**. Structured contraceptive counseling: a randomized control trial. Contraception 2010; 82(2):188.
39. Guerrero J, Castaño P, Rosario L, **WESTHOFF C**. Music as an auxiliary analgesic during first trimester surgical abortion: a randomized control trial. Contraception 2012; 82(2):184.
40. Hall K., Reame N., O’Connell K., Davis A. Rickert V, **WESTHOFF C**. Eating disordered symptoms, perceived weight gain, and oral contraceptive discontinuation in family planning patients . Presented at: North American Society for Pediatric and Adolescent Gynecology conference, Las Vegas NV, 4/2010. *Sally Perlman Best Poster Presentation Award.*
41. Siddiqui A, **WESTHOFF C**. Barriers to accessing voluntary postpartum female tubal sterilization among minority and low-income women. Presented at: STFM, Vancouver BC, 2010.
42. Dempsey A, Roca C, **WESTHOFF C**. Vaginal estrogen supplementation during Depo Provera initiation. Presented at: ARHP, Los Angeles, CA, 2009.
43. Dinger J, Heinermann AJ, **WESTHOFF C**. First results from the international active surveillance study on oral contraception (inas-oc). Presented at: ACOG, Chicago, IL, 2009.
44. Brinton L, Lamb E, Moghissi K, Scoccia B, **WESTHOFF C**. Cancer risk among infertile women with androgen excess and menstrual disorders (including polycystic ovarian syndrome). Presented at: American Society for Reproductive Medicine Annual Meeting, Atlanta, GA, 10/2009.
45. Wiegerinck MMJ, Jones HE, O’Connell K, Lichtenberg ES, Paul M, **WESTHOFF CL**. Medical abortion practices: a survey of National Abortion Federation members in the United States Presented at: ARHP Annual Meeting, Washington, DC, 2008.
46. Chen, B., Reeves, M., Creinin, M., Gilles, J., Barnhart, K., **WESTHOFF C**., Zhang, J. Misoprostol for Treatment of Early Pregnancy Failure in Women with Prior Uterine Surgery. Contraception 2007; 76:133.
47. Jones, KC, **WESTHOFF C**, Robilotto C, Edwards S, Heartwell S, Zieman, M. Smoking and Oral Contraception. Contraception 2007; 76:158.
48. Dinger JC, Heinemann, LAJ, **WESTHOFF CL**. Impact of oral contraception on public health. Final results from the European active surveillance (euras) study. Presented at ACOG 55th Annual Clinical Meeting, San Diego CA, 5/2007.
49. Castaño PM, **WESTHOFF CL**. A new tool for assessing the folate status of reproductive-aged urban Latina women. Presented at: ACOG 55th Annual Clinical Meeting, San Diego, CA, 5/2007. Published in: Obstet Gynecol 2006; 107: 44-45S.
50. Castaño PM, Andres R, Lara M, **WESTHOFF CL.** Assessing feasibility of text messaging to improve medication adherence. Presented at: ACOG 55th Annual Clinical Meeting, 5/2007. Published in: Obstet Gynecol 2006; 107:40S (suppl).
51. Nelson, Al, **WESTHOFF C**, Schnare, S. Evaluation of a 91-day extended regimen oral contraceptive continuation rates. Presented at: ARHP Annual Meeting, Minneapolis, MN, 9/2007. Published in: Contraception, 2007; 76:172.
52. Castaño PM, Horowitz D, **WESTHOFF CL**. Folate status of reproductive-aged urban Latina women . Presented at: APHA 133rd Annual Meeting, 12/2005.
53. Koenemann, S., Kalmuss, D., **WESTHOFF C**., Cushman, L., Robilotto, T, Podolsky, R, Horowitz, D. How Reasons for Prior Pill Discontinuation Affect the Likelihood of Continued OC Use. Presented at: APHA 33rd Annual Meeting and Expo, Philadelphia PA, 12/2005.
54. Chertok J, Castano PM, **WESTHOFF CL**. Knowledge of folic acid and intake in reproductive-aged minority women. Presented at: 55th AMSA Annual Meeting, 03/2005.
55. **WESTHOFF C**, Osborne, L, Schafer, J, Morroni, C. Three-cycle bleeding patterns, vaginal ring vs. low-dose OC: An RCT using immediate initiation. Presented at: ASRM 60th annual meeting, Philadelphia PA, 2004.

1. **WESTHOFF C**, Osborne, L, Schafer, J. Vaginal ring vs. low-dose OC: An RCT using immediate initiation, rates of first-cycle ovulation. Presented at: ASRM 60th annual meeting, Philadelphia PA, 2004.
2. Teal SB, **WESTHOFF C**, Creinin MD. Predictors of pain, bleeding and acceptability of medical abortion. Contraception 2004; 70:260.
3. Davis AR, O’Connell KJ, Gallagher N, **WESTHOFF C**. Oral contraceptives for dysmenorrheal in adolescent girls: a placebo-controlled trial. Presented at: ARHP annual meeting, Washington DC, 2004. Published in: Contraception 2004; 70:251-264.
4. Sneed R, **WESTHOFF C**, Johnson S. Assessing the predictive power of the transtheoretical model for oral contraceptive continuation. Contraception 2004; 70:256.
5. Schafer J, **WESTHOFF C**, Osborne L. Immediate acceptability and satisfaction with initiation of the contraceptive vaginal ring. Contraception 2004; 70:252.
6. O’Connell KJ, **WESTHOFF C**. Combined hormonal contraception and weight gain: A systematic evidence review of observational studies. Contraception 2004; 70:256.
7. **WESTHOFF C**, Robilotto, Richmond A, Cushman LF and Kalmuss DS. Three-month continuation rates after immediate initiation of oral contraceptives. ACOG 2004; 103(4):14s(suppl).
8. Creinin MD, Zhang J, Gilles J, Barnhart K, **WESTHOFF C**, Frederick M. Medical management with misoprostol for early pregnancy failure. Contraception 2004; 70:251-264.
9. Kleinhaus K, **WESTHOFF C**, Kerner B. An assessment of male partner influence on contraception. Contraception 2003; 68(2):151.
10. Sneed R, Hutchko M, Robilotto T, Johnson S and **WESTHOFF C**. Using a health behavior model to predict oral contraceptive continuation. Contraception 2003; 68(2):139.
11. Murphy PA and **WESTHOFF C**. Effects of St. John’s Wort on oral contraceptive. Presented at: ARHP annual meeting, La Jolla CA, 2003.
12. Morroni C, Grams M, Tiezzi L and **WESTHOFF C**. Novel approach to initiation of the Depo-Medroxy Progesterone acetate contraceptive injection. Contraception 2003; 68(2):139.
13. Brinton LA, Lamb E, Moghissi K, Scoccia H, Mabie J, Althuis M and **WESTHOFF C**. Ovarian cancer risk associated with varying causes of infertility. Presented at: ASRM annual meeting, San Antonio, TX, 2003.
14. O’Connell KJ, Davis AR, Osborne LM and **WESTHOFF C**. A placebo-controlled trial of oral contraceptive for dysmenorrheal in adolescent girls: methodological challenges and surprises. Contraception 2003; 68(2):144.
15. **WESTHOFF C** and Matseoane D. Papanicolaou screening after postpartum tubal ligation. Contraception 2003; 68(2):145.
16. Barnhart KT, Zhang J, Giles J, **WESTHOFF C**, Creinin M, and Frederick Margaret. Hormonal predictors of successful medical management of a nonviable first-trimester gestation with Misoprostol. Obstet Gynecol 2003; 101(4):515
17. Gilles J, Creinin M, Barnhart K, **WESTHOFF C**, Frederick M, Zhang J for the NICHD Management of Early Pregnancy Failure Trial group. Wet vs. dry intravaginal misoprostol application for treatment of early pregnancy failure. Presented at: ASRM Annual Meeting, Seattle WA, 10/2002.
18. Davis AR, Robilotto CM, **WESTHOFF C**, Forman S. Bleeding patterns after misoprostol treatment of early pregnancy failure. Presented at: ARHP annual meeting, Denver CO, 9/2002.
19. Schaff E, Fielding S, **WESTHOFF C**. Mifepristone and oral versus vaginal misoprostol: A randomized trial. Presented at: NAF Annual Meeting, San Jose CA, 4/2002.
20. Bell D, Tiezzi L, Vaughan R, Armstrong B, Cohall A, and **WESTHOFF C**. A simple STD urine screen and single dose treatment program for men. Presented at: APHA Annual Meeting, Philadelphia PA, 2002.
21. Kerns J, **WESTHOFF C**, Cushman L, Morroni C, and Murphy P. Oral contraceptive continuation rates: A novel oral contraceptive initiation method and partner influences. Presented at: ARHP Annual Meeting, Washington DC, 12/2001.

1. **WESTHOFF C**, Morroni C, Kerns J, Aikings-Murpy P. A novel oral contraceptive initiation method: assessment of bleeding patterns. Presented at: ARHP Annual Meeting, Washington DC, 12/2001.
2. **WESTHOFF C**, Kerns J, Morroni C, Tiezzi L, and Aikins-Murphy P. Quickstart: a novel oral contraceptive initiation method. Presented at: APHA Annual Meeting, Atlanta GA, 10/2001.
3. **WESTHOFF C**, Morroni C, Kerns J, Aikings-Murpy P. A novel oral contraceptive initiation method: assessment of bleeding patterns. Presented at: ASRM annual meeting, Orlando FL, 10/2001.
4. Davis AR, Nowygrod S, Egan C, Shabsigh R, **WESTHOFF C**. The influence of vaginal bleeding on the sexual behavior of Hispanic women and men. Presented at: ARHP annual meeting, Chicago IL, 9/2000.
5. Picardo L, Singh D, **WESTHOFF C**. MVA versus mifepristone: Patient costs, personnel costs, and quality of life comparisons. Presented at: ARHP annual meeting, Chicago, IL, 9/2000.
6. Picardo L, **WESTHOFF C**, Singh D. Cost effectiveness and health related quality of life in women undergoing medical and surgical abortion. Presented at: NAF annual meeting, Pittsburg, PA, 4/2000. *Prize winning paper.*
7. Allen R, Denonno L, **WESTHOFF C**, Schaff E. Characteristics of medical abortion treatment failures. Presented at: NAF annual meeting, Pittsburg, PA, 4/2000.
8. Denonno L, **WESTHOFF C**, Schaff E. Timing of symptom onset after mifepristone and misoprostol used at 24, 48, or 72 hours after mifepristone. Presented at: NAF annual meeting, Pittsburg, PA 4/2000. *Prize winning paper.*
9. Guise JM, Aickin M, Helfand M, Peipert J, **WESTHOFF C**. Screening for bacterial vaginosis in pregnancy: a meta-analysis. Presented at: ACOG Annual Clinical Meeting, San Francisco, CA, 5/2000.
10. Soren K, Murphy P, Davis A, **WESTHOFF C**. Contraception for adolescents with chronic illnesses: A demonstration project. Society of Adolescent Medicine Meeting, New Orleans, LA, 3/2000.
11. Britton J, **WESTHOFF C**, Gammon M, Wright T. The relation between lactose and benign ovarian tumors in a case-control study. Presented at: SER annual meeting, 6/1999.
12. Davis A, **WESTHOFF C**, De Nonno L, Infantino S. Vaginal bleeding after abortion. Presented at: NAF Annual Meeting, 1999.
13. Elul B, Worhaindo A, Pearlman E, Simonds W, **WESTHOFF C**. What do women think about a home-use mifepristone-misoprostol medical abortion regimen? Presented at: NAF Annual Meeting, 1999.
14. **WESTHOFF C**. An early pregnancy prevention program in New York City School-based Clinics. Presented at: FIGO, Copenhagen, Denmark, 8/1997.
15. Pirog E, Heller D, **WESTHOFF C**. Tumor differentiation but not duration of symptoms correlates with stage of endometrial adenocarcinoma at hysterectomy. Presented at: FIGO, Copenhagen, Denmark, 8/1997.
16. Neu N, Grumet S, Saiman L, **WESTHOFF C**, McMahon D. Chlamydia genital disease: Novel risk factors in a low prevalence population. Presented at: Eastern Society for Pediatric Research Meeting, 3/1997.
17. **WESTHOFF C**, Oddens B. Women's views and knowledge of oral contraceptives: U.S. and European experience. Presented at: FIGO, Montreal, Canada, 9/1994.
18. Heller D, Drosinos S, **WESTHOFF C**, Tancer ML. Accuracy of tumor grade assigned at initial endometrial sampling. Presented at: ACOG Annual Meeting, Orlando, FL, 5/1994.
19. Heller D, **WESTHOFF C**, Katz N, Gordon R. The relationship between perineal cosmetic talc usage and ovarian talc fiber burden. Presented at: American Society of Clinical Pathology, 5/1994.
20. **WESTHOFF C**, Marks F, Rosenfield A. International Conference on IUD's. New York, NY. 4/1992.
21. Lesser K, Marks F, **WESTHOFF C**: The effect of untreated syphilis on the maternal characteristics of labor and delivery. Presented at: Society of Perinatal Obstetricians Annual meeting, Orlando, FL, 2/1992.
22. Marks F, Kelly A, **WESTHOFF C**, Rosen M. The 80-hour work week II: Resident preparation for life after residency. Presentation at: CREOG and APGO Annual meeting, Orlando FL, 3/1992.
23. **WESTHOFF C**, Gentile G, Helbig D, Driscoll B. Prospective evaluation of menstrual changes in women choosing tubal sterilization . Presented at the Association of Reproductive Health Professionals, Annual meeting Dallas, TX, 10/1990.
24. **WESTHOFF C**, Minkoff H, Landesman S, Fikrig S. The risk of AIDS or AIDS-related complex in infants of HTLV-III positive mothers. Presented at: Infectious Disease Society for Obstetrics-Gynecology Annual Meeting, Boston, MA, 8/1986.

14) **Selected Presentations: (2000-present)**

1. University of Cincinnati Department of Obstetrics and Gynecology. Sam Seeds Visiting Professorship. Cincinnati, OH, June 2019.
2. North American Forum on Family Planning. Michael S. Burnhill Memorial Lecture. New Orleans, October 2018.
3. All India Institute of Medical Sciences. Initiation of Hormonal Contraception. Delhi, India, October 2017.

1. Indian Obstetrics and Gynecology (journal). Sixth Annual Dr. Stya Paul Awards, Oration Lecture. A pill in time saves nine. Delhi, October, 2017.
2. American Society of Emergency Contraception Annual Meeting. LNG and UPA EC in obese women: findings from a pharmacokinetic study. Washington DC, 9/2016.
3. University of Pittsburgh. Mitch Creinin Lectureship Presentation. Department of OB/GYN and Department of Medicine Grand Rounds. 4/2016
4. University of Illinois at Chicago. Visiting Professor. Resident Research Day. 5/2015
5. Hofstra North Shore –LIJ School of Medicine. Rose and Wilfred P. Cohen Lectureship Series. Contraception and Venous Thromboembolism. 2/2015
6. ACOG 2014 Annual District II Meeting. Obesity in Ob/Gyn. 10/2014.
7. University of North Carolina. Visiting Professor. Resident Research Day. 5/2014.
8. University of California San Francisco. The Ernest W. Page Visiting Professor Edward Hill MD Lecture. 28th Annual Resident Research Day. 4/2014.
9. Yale University. Visiting Professor. Department of Ob/Gyn Grand Rounds. 12/2013.
10. University of Ottawa. Visiting Professor. Department Ob/Gyn Grand Rounds. 6/2013.
11. Queen’s University. Visiting Professor. Department Ob/Gyn Resident Research Day. 5/2013.
12. Dartmouth-Hitchcock Medical Center. Key Note Lecture. Resident Research Day. 5/2013.
13. Wayne State School of Medicine. Kamran S. Moghissi, M.D. Lecture. Wayne Day 2011: “Family Planning: 50 Years After the Pill.” 12/2011.
14. University of New Jersey Medical School. Visiting Professor. Resident’s Research Day. 6/2007.
15. Wayne State University. David Feld Memorial Lecture. 6/2005.
16. Mt. Sinai School of Medicine. 9th Annual Pediatric, Adolescent and Young Adult Gynecology Conference, Innovations in Contraceptive Initiation. 3/2005.
17. Royal College of Obstet Gynecol (London, U.K.). Contraceptive Continuation. 2/2005.
18. Miami Ob/Gyn Society. President’s Guest Speaker. Innovations in Contraception. 12/2004.
19. Columbia University. Distinguished Lecture Series in Reproductive Endocrinology, Cancer after Infertility Treatment. 11/2004.
20. New York State Department of Health. The Family Planning Benefit Program: a Medicaid Waiver. 11/2004.
21. American Society of Reproductive Medicine. 60th annual meeting (Philadelphia, PA). Symposium Chair and Speaker. Cancer after Infertility Treatment. 10/2004.
22. Harvard University, Radcliffe Institute of Advanced Study. Speaker. Reproductive Health in the 21st Century, New Technologies and the Unsettling of the Natural. 10/2004.
23. Harvard Medical School. Lader Lecture. RU486, Plan B, and the Pharmacological Revolution in Reproductive Rights. 5/2004.
24. San Francisco GYN Society. Innovations in Hormonal Contraception. 1/2004.
25. Brown University, Women’s and Infant’s Hospital. Visiting Professor. Resident Research Day. 6/2002.
26. University of Michigan. Abram Sager MD Lectureship. Resident Paper Day. 5/2002.
27. CDC Department of Health and Human Services. Plenary lecture, Chlamydia Screening and Infertility Prevention. 2002 National STD Prevention Conference (San Diego, CA). 3/2002.
28. International Federation of Fertility Societies. Chairperson. Nuvaring Symposium (Melbourne, Australia). 11/2001.
29. Washington State University, College of Pharmacy. Allen I. White Lecture. Medical Abortion, Clinical Aspects. 4/2001.
30. Medical College of Georgia. Serono Symposium: Frontiers in Reproductive Endocrinology (Washington, DC). Innovations in Contraception. 4/2001.
31. New York City Council RU486 Public Hearing: The Impact of Possible FDA Restrictions on its Use and Distribution. 9/2000.
32. International Federation of Gynaecology and Obstetrics. New Developments in Injectable Contraception. Annual Meeting (Washington, DC). 9/2000.
33. The Congress of the European Society of Contraception. Long Term Contraception (Ljubljana, Slovenia) 6/2000.
34. University of Kansas Medical Center (Kansas City, KS). Visiting Professor, Evidence Based Medicine: What Does It Really Mean? Resident Research Day. 6/2000